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Abstract 
The protein kinases (PKs) belong to the largest single family of enzymes, 
phosphotransferases, which catalyze the phosphorylation of other enzymes and proteins 
and function primarily in signal transduction. Consequently, PKs regulate cell 
mechanisms such as growth, differentiation, and proliferation. Dysfunction of these 
cellular mechanisms may lead to cancer, a major predicament in health care. Even though 
there is a range of clinically available cancer-fighting drugs, increasing number of cancer 
cases and setbacks such as drug resistance, constantly keep cancer research active. 
 
At the commencement of this study an isophthalic acid derivative had been suggested 
to bind to the regulatory domain of protein kinase C (PKC). In order to investigate the 
biological effects and structure-activity relationships (SARs) of this new chemical entity, a 
library of compounds was synthesized. The best compounds induced apoptosis in human 
leukemia HL-60 cells and were not cytotoxic in Swiss 3T3 fibroblasts. In addition, the 
best apoptosis inducers were neither cytotoxic nor mutagenic. Furthermore, results from 
binding affinity assays of PKC isoforms revealed the pharmacophores of these isophthalic 
acid derivatives. The best inhibition constants of the tested compounds were measured to 
210 nM for PKC and to 530 nM for PKC. 
 
Among natural compounds targeting the regulatory domain of PKC, the target of 
bistramide A has been a matter of debate. It was initially found to activate PKC; 
however, actin was recently reported as the main target. In order to clarify and to further 
study the biological effects of bistramide A, the total syntheses of the natural compound 
and two isomers were performed. Biological assays of the compounds revealed 
accumulation of 4n polyploid cells as the primary mode of action and the compounds 
showed similar overall antiproliferative activities. However, each compound showed a 
distinct distribution of antimitotic effect presumably via actin binding, proapoptotic effect 
presumably via PKC, and pro-differentiation effect as evidenced by CD11b expression. 
Furthermore, it was shown that the antimitotic and proapoptotic effects of bistramide A 
were not secondary effects of actin binding but independent effects. 
 
The third aim in this study was to synthesize a library of a new class of urea-based type 
II inhibitors targeted at the kinase domain of anaplastic lymphoma kinase (ALK). The best 
compounds in this library showed IC50 values as low as 390 nM for ALK while the initial 
low cellular activities were successfully increased even by more than 70 times for NPM-
ALK-positive BaF3 cells. More importantly, selective antiproliferative activity on ALK-
positive cell lines was achieved; while the best compound affected the BaF3 and SU-
DHL-1 cells with IC50 values of 0.5 and 0.8 μM, respectively, they were less toxic to the 
NPM-ALK-negative human leukemic cells U937 (IC50 = 3.2 μM) and BaF3 parental cells 
(IC50 = 5.4 μM). Furthermore, SAR studies of the synthesized compounds revealed 
functional groups and positions of the scaffold, which enhanced the enzymatic and cellular 
activities. 
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Amino acid 3-Letter symbol 
1-Letter 
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Compound and inhibitor constants and parameters 
 
EC50 the concentration of an compound which causes 50% of a maximal effect 
IC50  the concentration of an inhibitor which causes 50% inhibition 
IG50 the concentration of an inhibitor which causes 50% growth inhibition 
Ki  inhibitor dissociation constant 
Kd dissociation constant
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1 Introduction 
The PKs account for about 1.7% of the proteins encoded by the human genome, and thus belong 
to the largest single family of enzymes. 1 With its over 500 members, the main role of PKs is 
signal transduction and therefore they regulate the growth, differentiation, proliferation and 
various cell mechanisms. 2 However, when dysfunction of these cellular mechanisms occurs, 
they subsequently may cause diseases such as cancer. 2 With an estimation by the Finnish Cancer 
Registry of a quarter more cancer cases in Finland in year 2020, 3 and by the American Cancer 
Society of over 1,500,000 new cancer diagnoses in USA alone for the year 2010, 4 finding highly 
specific therapeutic anti-cancer drugs is an important challenge for health care the world around. 
 
Therapies for diseases such as cancer may include the inhibition of growth-related kinases. 2 
Probably one of the most studied PKs is the PKC (EC 2.7.11.13) family. When PKC was found 
in 1977, 5, 6 it had not been linked to signal transduction. However, shortly after this, the first 
isoform of PKC was shown to be calcium-activated and phospholipid-dependent, 7 
diacylglycerol-induced, 8 and coupled to the activation of G-protein-coupled receptors, 9 thus 
linked to signal transduction. Since then, PKC research has only accelerated. At the moment, 
PKC has been suggested as a potent therapeutic target not only in cancer, 10, 11 but also in 
neurological diseases; 12 especially Alzheimer’s disease (AD), 13-15 immunological diseases, 16, 17 
and cardiovascular diseases. 18-20 
Targeting the kinase domain of PKC has yielded two isoform selective PKC inhibitors so 
far: ruboxistaurin (LY333531) 21 and enzastaurin (LY317615), 22 however, these inhibitors 
inhibit also other kinases. 23, 24 The main stumbling block has been the highly conserved ATP-
binding pocket of PKC, however, targeting the regulatory domain could more easily provide 
PKC selective compounds. Consequently, one part of this thesis deals with known natural and 
synthetic compounds targeted to bind the regulatory domain of PKC as well as the development 
of novel compounds. 
 
A relatively new PK target is ALK (EC 2.7.10.1). In 1988, a chromosomal translocation in 
anaplastic large cell lymphomas (ALCLs) was described by several groups, 25, 26 and in 1994 the 
fusion product of the chromosomal translocation was identified. 27, 28 Since then, several other 
fusion products of ALK have been discovered. 29 The function of the wild type (WT) ALK is still 
poorly known. This receptor tyrosine kinase (RTK) has been shown to have a part in the 
development of the central and peripheral nervous system 30 as well as be involved in neuronal 
cell differentiation and regeneration, synapse formation and muscle cell migration. 31 In contrast, 
fusion products of ALK have constitutive kinase activity and are highly oncogenic. 32 Recently 
the dual kinase inhibitor crizotinib was shown to inhibit fusion products of ALK and is now in 
clinical trials (phase I-III) for the treatment of lung cancer. 33 However, there is a constant need 
for new inhibitors in ALK-positive tumors since crizotinib resistant cell lines have already been 
obtained. 34 
Inhibitors targeting only the ATP-binding pocket of the kinase domain are prone to tumor 
resistance and are more difficult to make specific. Preparing inhibitors that also target residues 
11 
 
outside of the site, 35 or exclusively outside the pocket, 36 would increase specificity among 
kinases. In addition, inhibitors that target the inactive conformation of the kinase further increase 
specificity. 36, 37 Therefore, the second part of this thesis deals with the development of novel, as 
well as known natural and synthetic, kinase domain-targeted ALK inhibitors. 
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2 Review of the literature 
2.1 Protein kinases and the phosphoryltransfer reaction 
The PKs, also called phosphotransferases, are enzymes that catalyze the phosphorylation of 
proteins, such as enzymes. 38 The superfamily of PKs can be divided into several classes 
according to which amino acids are phosphorylated on the target proteins; serine/threonine 
kinases (EC 2.7.11.1), tyrosine kinases (EC 2.7.10.1 and 2.7.10.2) and dual-specificity kinases 
(EC 2.7.12.1). 39 The latter group phosphorylates all the three above-mentioned amino acids. In 
addition, a fourth and more rare group of kinases is that which phosphorylates histidines (EC 
2.7.13.3). In addition to phosphorylation specificity of the above-mentioned amino acids, 
specificity among substrates containing those amino acids can also be obtained. 40 In these cases, 
the adjacent amino acids infer the specificity of these substrates. 
In the phosphoryltransfer reaction, a PK binds adenosine-5´-triphosphate (ATP, 1), the target 
protein moves to the kinase-ATP complex, and the PK transfers the -phosphate group of ATP to 
the hydroxy group of the target protein (Figure 1). 39 The order in which the PK binds ATP and 
 
Figure 1 Phosphorylation of target proteins by protein kinases; A) a protein kinase binds ATP, B) a 
target protein binds to the protein kinase-ATP complex, C) the protein kinase transfers a 
phosphate group from ATP to the target protein and the phosphorylated target protein 
leaves the complex, D) a protein kinase-ADP complex and a phosphorylated target protein 
as products. Adenosine-5´-triphosphate (ATP, 1), adenosine-5´-diphosphate (ADP, 2). 
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the target protein is not always identical, the opposite order can also be the case. The same is true 
for the order of the release of the phosphorylated product and adenosine-5´-diphosphate (ADP, 
2); which dissociates first from the PK can vary from kinase to kinase. The phosphorylation of a 
target enzyme usually leads to its conformational change, consequently activating or deactivating 
the target enzyme. Other effects caused by phosphorylation of the target proteins are subcellular 
relocation and association with other proteins. 1, 41 
The phosphoryltransfer reaction takes place in the highly conserved kinase domain of PKs. 
The reaction involves a cascade of interactions between the substrate, ATP and the PK (Figure 
2). 39, 42 For example, in the catalytic site of protein kinase A (PKA, EC 2.7.11.11), the Asp166 
carboxylate is thought to act as a catalytic base to the serine hydroxy of the substrate (residue 
numbering corresponds to that of PKA). 43 Alternatively, the Asp166 is suggested to act as an 
orientating residue, as such the aspartate would orientate the hydroxy group of the substrate 
towards the -phosphate of ATP. 44 In contrast, the latest quantum mechanical/molecular 
 
Figure 2 The distances between the residues, substrate protein, ATP/ADP and water molecules in a 
phosphoryltransfer reaction of protein kinase A (PKA). 42 The structures represent the A) 
reactant, B) the transition state and C) the product. The numbers indicate the optimized 
bond lengths in ångströms (Å) and were obtained from quantum mechanical/molecular 
mechanics simulations. Adenosine (ADN); Asn171 (N171); Asp168 (D166); Lys168 (K168) 
and Thr201 (T201). Adapted with permission from ref. 42. Copyright 2011 American 
Chemical Society. 
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mechanics simulations suggest that Asp166 functions as a hydrogen bond acceptor late in the 
reaction process (Figure 2C). 42 Other residues which are in close proximity to the 
phosphoryltransfer site are Asn171, Lys168 and Thr201 (Figure 2 and Figure 3). 
 
A              B 
 
Figure 3 The catalytic site of the crystal structure of PKA in complex with a peptide inhibitor and ATP 
or ADP. 43, 45 A) The hydroxy group of the serine residue (Ser377) of the unphosphorylated 
peptide and ATP (Atp355). Ser377, ATP and the residues which are thought to be involved in 
the phosphoryltransfer reaction are represented in ball and stick representation and colored 
by atom type, hydrogen bonds are denoted as green spheres. The figure was created by 
deleting ADP (Adp381) from the crystal structure of PKA (PDB-code: 1JBP) 43 and adding 
ATP (Atp355) from an other crystal structure of PKA (PDB-code: 1ATP) 45 to 1JBP. B) The 
phosphorylated hydroxy group of the serine residue (Sep377) in the substrate peptide and 
ADP (Adp381). Represented as in A). The figure was created by adding ADP (Adp381) from 
1JBP 43 to the crystal structure of 1JLU. 43 The figures were created using ICM-Browser 
(version 3.7-2a, MolSoft L.L.C.). 
In addition to these residues, several other amino acids help to coordinate ATP in the binding site 
by forming hydrogen bonds to it (Figure 4). First, the adenine ring of ATP is hydrogen-bonded to 
the hinge region residues Glu121 and Val123 as well as to residue Thr183 (numbering as for 
PKA). 45 The ribose moiety of ATP is hydrogen-bonded to amino acids Glu127 and Glu170 and 
the -, - and -phosphates of ATP are bonded by the P-loop residues Ser53, Phe54 and Gly55 as 
well as residues Lys72 and Lys168. Furthermore, the Mg2+ ions are coordinated with the help of 
residues Asn171 and Asp184 as well as with the help of the -, - and -phosphate groups (in 
Figure 4 the Mg2+ ions are replaced with Mn2+ ions). 
In the next chapters, the PKC and ALK enzymes will be discussed in more detail (Chapters 
2.2 and 2.3, respectively). 
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Figure 4 ATP is coordinated in the catalytic site of PKA by a nest of hydrogen bonds (PDB-code: 
1ATP). 45 ATP and residues forming hydrogen bonds (green spheres) to ATP are presented 
in ball and sticks representation and colored by atom type. The Mn2+ ions (Mn352 and 
Mn351) are shown as grey dots. For the sake of clarity, a part of the P-loop (see Chapter 
2.3.2.) was deleted. The figure was created using ICM-Browser (version 3.7-2a, MolSoft 
L.L.C.). 
 
2.2 Protein kinase C 
The PKC isoenzymes are involved in intracellular signal transduction cascades and in cellular 
events such as proliferation, differentiation and apoptosis. 9, 46 PKCs belong to the larger subclass 
of PKs termed the adenine-guanine-cytosine (AGC) kinases and are serine/threonine kinases. 41 
The PKC family is divided into three categories according to the structure of the regulatory 
domain and cofactor requirements, and consists of at least ten mammalian isoenzymes. 
According to these requirements, the PKCs are grouped into classical or conventional PKCs 
16 
 
(cPKCs, subtypes , I and II, and ), the novel PKCs (nPKCs, subtypes , , 	 and 
) and the 
atypical PKCs (aPKCs, subtypes , /) (Table 1). 41 All PKCs are dependent on anionic 
phospholipids for activation, with phosphatidyl-L-serine (Ptd-L-Ser, 3) being the most 
important. 47 In addition, cPKCs require both Ca2+ and 1,2-diacylglycerol (DAG, 4) for 
activation, whereas nPKCs require only DAG (4). The third group, the aPKCs, requires neither 
DAG (4) nor Ca2+ for activation. 
DAG (4), a central intracellular second messenger, selectively interacts with proteins 
containing a C1 domain. The production of DAG (4) and Ca2+ is a result of a signal transduction 
cascade, which starts from the activation of G protein-coupled receptors and receptor-tyrosine 
kinases. 48, 49 When activated, these in turn activate phospholipase C (PLC, EC 3.1.4.11), which 
hydrolyzes the phospholipid phosphatidylinositol bisphosphate (PIP2, found in membranes) to 
give inositol 1,4,5-triphosphate (IP3) and DAG (4). 50 DAG (4) stays bound to the cell membrane 
but IP3 migrates to the endoplasmic reticulum, where Ca2+ is consequently released into the 
cytosol and activates PKC. 
Phorbol esters (5) are products obtained from croton oil, which is derived from the seeds of 
Croton tiglium L. 51 The phorbol esters (5) were shown to bind similarly as DAG (4) to the C1 
domain of PKC, however, many of the phorbol esters are tumor promoting. 52-54 
 
Table 1. Cofactors needed to activate the different isoforms of PKC. a 
Isoform Cofactors 
 Ptd-L-Ser (3) DAG (4) Ca2+ 
cPKC (, I+II, ) + + + 
nPKC (, , 	, 
) + + - 
aPKC (, /) + - - 
a Ptd-L-Ser (phosphatidyl-L-serine), 1,2-diacylglycerol (DAG), classical/conventional PKC (cPKC), novel PKC 
(nPKC) , atypical PKC (aPKC), needed (+), not needed (-). 
 
The PKCs are non-receptor kinases, which in the inactive conformation can be found in the 
cytoplasm of cells. 41 Once the enzyme is activated, it localizes to various membranes, 55, 56 such 
as the plasma membrane, the perinuclear membrane 57 and the membrane of the Golgi 
apparatus. 58 In fact, the isoform-specific effects on cells are a result of the different subcellular 
localizations of the isoforms of PKC. 11, 59 The effects of PKC on apoptosis and proliferation 
form the basis for targeting PKC. PKC has been correlated to a number of conditions, including 
cancer, 10, 11 neurological diseases; 12 especially AD, 13-15 immunological diseases, 16, 17 and 
cardiovascular diseases. 18-20 
It is important to choose the right isoform of PKC when validating the therapeutic target 
enzyme, since the different isoforms of PKCs show specific biological effects. 60 Inhibition or 
activation of the target isoform also has to be taken into consideration as the different isoforms 
can produce opposite outcomes. For example, activation of PKC before ischemia protects the 
heart by mimicking preconditioning, whereas inhibition of PKC during reperfusion protects the 
17 
 
heart from reperfusion-induced damage. 61 Hence, isozyme-selective PKC therapeutics are 
greatly needed. 
 
Figure 5 The structures of phosphatidyl-L-serine (Ptd-L-Ser, 3), 1,2-diacylglycerol (DAG, 4) and 
phorbol esters (5). Functional groups that interact with the C1 domain are highlighted. 
 
2.2.1 Structure, activation and regulation 
 
Structure 
 
The PKCs consist of a highly conserved C-terminal catalytic domain and a less conserved N-
terminal regulatory domain (Figure 6). 62 The catalytic domain contains the kinase part, where 
the ATP-binding site can be found. This site is highly conserved among PKs; the kinase domain 
of ALK will be discussed in more detail in Chapter 2.3.2. 
The Ca2+-binding C2 domain and the DAG/phorbol ester-binding C1 domain can be found in 
the regulatory part of cPKCs (Figure 6). Furthermore, the C1 domain consists of a tandem repeat 
  
 
Figure 6  Structures and domains of protein kinase C isoforms. PS = pseudosubstrate, PB1 = Phox 
and Bem 1. 
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sequence of about 50 residues, which is termed C1a and C1b. Similar to the cPKCs, the nPKCs 
also contain the tandem C1 domains but the positions are switched in the linear sequence 
compared to the cPKCs (Figure 6). As mentioned earlier, the C2 domain of nPKCs does not bind 
to Ca2+; hence it is called a C2-like domain. The aPKCs do not have a Ca2+-binding C2 domain 
but instead a protein-protein interaction PB1 (Phox and Bem 1) domain. In addition, the aPKCs 
have an atypical C1-domain, because it is a single copy of the C1 domain and it does not bind 
DAG (4) or phorbol esters (5). Furthermore, all of the PKC isoforms have an autoinhibitory 
pseudosubstrate domain. 
The C1 domain will be discussed in more detail in Chapter 2.2.2. 
 
 
Priming phosphorylations of PKC 
 
Unphosphorylated PKCs can be found in the cytoplasm/detergent-insoluble fraction of cells and 
require two (aPKCs) or three (cPKCs and nPKCs) phosphorylations to fully mature (priming 
phosphorylations). 63, 64 The first modification is an autophosphorylation or a phosphoinositide-
dependent kinase 1 (PDK-1)-catalyzed phosphorylation of a threonine found in the activation 
loop (A-loop), a highly conserved motif of the catalytic domain. The phosphate group produces a 
negative charge in the peptide-binding surface of the domain and subsequently, stabilizes the 
active conformation. Next, a threonine/serine is phosphorylated at the conserved turn motif. The 
turn motif can be found at the C-terminal end of the catalytic domain and is usually flanked by 
prolines. The incorporated negative charge further stabilizes the PKCs and is crucial for catalytic 
activity. 64 Once the turn motif of the mature PKC is phosphorylated, selective 
dephosphorylation(s) of another phosphate group(s) does (do) not result in any loss of activity. 
Hence, a phosphate group at the turn motif of a mature PKC is all that is needed for catalytic 
activity. The third modification is an autophosphorylation (for cPKCs) of a threonine/serine 
residue 19 residues C-terminal to the turn motif. 65 This conserved FXXFS/TF/Y motif is flanked 
by hydrophobic residues and is therefore also called the hydrophobic motif. Among the nPKCs, 
this motif can also be transphosphorylated. 66 In contrast to the cPKC and nPKC isoforms, 
aPKCs do not have the corresponding threonine/serine residue at the hydrophobic motif. 
However, this residue is replaced by a glutamic acid residue and consequently, the aPKCs 
contain the needed negative charge in the hydrophobic moiety. In addition to these 
phosphorylations, other serine/threonine residues of the enzyme can also be phosphorylated. 41 
 
 
Activation and regulation of PKC 
  
PKCs are allosterically regulated by their pseudosubstrate. 67, 68 In the inactive conformation, the 
pseudosubstrate is bound to the catalytic domain and inhibits enzyme activity (Figure 7A). In 
addition, the C1b domain is in close proximity to the catalytic domain, clamping the highly 
conserved NFD-motif (see Chapter 2.2.2.) off the ATP-binding site resulting in a low activity 
state. 69 The activation cascade starts when the C2 domain binds Ptd-L-Ser (all isoforms) and 
Ca2+ (only cPKCs). This causes the C2 domain to translocate to the cell membrane (Figure 7B). 
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Next, the C1a domain (of cPKCs and nPKCs) binds to DAG (4)/phorbol ester (5), causing it to 
translocate to the membrane. As a result, the enzyme undergoes conformational changes, causing 
the pseudosubstrate to move out from the ATP-binding site (Figure 7C). 41 However, the enzyme 
is not yet fully activated since the C1b domain is still located at the ATP-binding site. 69 Only 
after the C1b domain has bound to DAG (4)/phorbol ester (5) and translocated to the membrane, 
causing the interactions between the C1b and kinase domain to be lost, will the enzyme 
subsequently be activated (Figure 7D). The conformational change of the enzyme reveals the 
hinge region between the catalytic domain and the C2 domain. The hinge region becomes 
proteolytically labile, and if it is cleaved a constitutively active kinase domain is formed. 6 
DAG (4)/phorbol esters (5) and Ca2+ do not affect the activation or the regulation of aPKCs. 
41 In contrast, the regulation is affected by phospholipids, PDK-1, the PB1 domain and other 
proteins. 
 
Figure 7 Activation of cPKCs. A) In the inactive conformation, the pseudosubstrate is bound to the 
catalytic site of the kinase domain. B) The C2 domain binds Ca2+ and phosphatidyl-L-serine 
(Ptd-L-Ser, 3) and the domain localizes to the cell membrane. C) The C1a domain binds 
diacylglycerol (DAG, 4)/phorbol ester (5) at the cell membrane and a conformational 
change has moved the pseudosubstrate off the catalytic site. The C1b domain is still in front 
of the ATP-binding site, producing a low activity state of the catalytic site. D) The active 
conformation where the C1b domain is not anymore at the front of the catalytic domain but 
binds DAG (4)/phorbol ester (5) at the membrane. 
Once the PKCs are phosphorylated and subsequently activated, they become highly sensitive to 
dephosphorylation; membrane-bound PKC is two orders of magnitude more sensitive to 
dephosphorylation than is PKC found in the cytoplasm. 70 In addition, dephosphorylation and 
down-regulation of PKC also takes place if cells are activated by phorbol esters (5) for an 
extended time, leading to proteolysis in the detergent-insoluble fraction of cells. 71 Other 
regulation methods include caveolin-dependent targeting to endosomes, 72 ubiquitin-mediated 
proteolysis, 73, 74 and binding of the heat-shock protein 70 (Hsp70). 75 
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2.2.2 The C1 domain of protein kinase C 
 
The regulatory part of cPKCs and nPKCs contains two DAG-sensitive C1 domains named C1a 
and C1b, respectively. 62 The C1a and C1b domains do not have equal roles in the isoenzymes; 
e.g. the C1b domain of PKC binds phorbol 12-myristate 13-acetate (PMA, 6) with higher 
affinity than the C1a domain, 76 in contrast to PKC, where both the C1a and C1b domains 
equally respond to PMA (6) and target the enzyme to the membranes. 77 Furthermore, in the case 
of PKC, the binding affinity for DAG (4) is the opposite: the C1a domain binds DAG (4) with 
higher affinity than the C1b domain. 78 In contrast, the C1 domains of cPKCs (e.g. PKC) have 
an affinity for DAG (4) which is two orders of magnitude lower than the C1 domains of nPKCs 
(e.g. PKC), 79 which can be explained 80 by a single residue only found in the C1b domain of 
the cPKCs: Tyr123 (PKCII numbering). 69 In all other C1 domains this residue is tryptophan. In 
contrast, the aPKCs contain a single C1 domain which is not able to bind DAG (4) /phorbol 
esters (5). 
Until very recently (January 2011), 69 the only crystal structure available of a DAG 
(4)/phorbol ester (5)-binding C1 domain of PKC was that of a C1b domain of PKC complexed 
with phorbol 13-O-acetate (7, PDB ID: 1PTR, Figure 8a). 81 Other C1 domain structures 
available are obtained from NMR methods (PDB ID: 2ENN, 2ENZ, 2ELI, 2E73, 1TBN and 
1TBO). 82, 83 The crystal structure reveals an approximately 50 residues long sequence that 
contains two zinc finger structures where each zinc atom is coordinated by three cysteines and a 
histidine residue. The “bottom” third of the domain contains negatively charged amino acids and 
the “central” part of the domain is hydrophilic. The binding site of DAG (4) and phorbol esters 
(5) can be found in the hydrophobic “top” third of the domain, where a deep, narrow and polar 
groove can be found between two -sheets (Figure 8b). The C1 domain-DAG (4)/-phorbol ester 
(5) complex is thought to be partly buried in the membrane bilayer, 81, 84 hence the positively 
charged amino acids in the central part of the domain could interact with anionic membrane 
phospholipids and the negatively charged amino acids in the bottom of the domain could face the 
cytoplasm. Furthermore, to overcome an enthalpy penalty caused by interactions between the 
polar groove of the binding site and the bilayer, the ligands are thought to act as caps on the top 
part of the domain to produce a continuous hydrophobic surface and thus masking the polar 
groove. 81 
The crystal structure of the C1b domain complexed with phorbol 13-O-acetate (7) reveals pivotal 
hydrogen bonds between the ligand and the binding site (Figure 8 and Figure 9). 81 The 
carbonyls of Leu121 and Thr113 (residue numbering corresponds to that of PKCII) 69 at the 
bottom of the groove act as hydrogen bond acceptors for the C20 hydroxy of 7. In addition, the 
amide hydrogen of Thr113 acts as a hydrogen bond donor for the C20 hydroxy of 7. 
Furthermore, the carbonyl of Gly124 is hydrogen-bonded to the C4 hydroxy of 7, and the C3 
carbonyl is also hydrogen-bonded to the amide proton of the same residue (Gly124). Among the 
12,13-O-diesters of phorbols, the C13 carbonyl group is essential for high-affinity binding while 
the C12 carbonyl group is not. 85-87 This fact is illustrated by the inhibitor dissociation constant 
(Ki) values of the monoesters 12-O-decanoate (8) and 13-O-decanoate (9); ca. 380 nM and 10 
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Figure 8 The crystal structure of the PKCδ C1b domain complexed with phorbol 13-O-acetate (7, 2.2 
Å resolution, PDB ID: 1PTR). 81 Residue numbering corresponds to that of PKCβII (PDB 
ID: 3PFQ). 69 A) Side view of the structure. The pivotal polar functional groups of the 
phorbol ester involved in C1 domain recognition include the hydroxy groups in the carbon 
atoms C4 and C20 and the carbonyl group on C3. The carbonyls of Gly124, Leu121 and 
Thr113 are hydrogen bond acceptors (green spheres), and the amide protons of Gly124 and 
Thr113 are hydrogen bond donors (green spheres). The Cys and His residues coordinating 
the two zinc atoms (grey) are also shown. The phorbol ester and the residues are presented 
in ball and stick representation and colored by atom type. B) Top view of the binding pocket 
of the crystal structure. The surface is colored as follows: oxygen atoms (red), nitrogen 
atoms (blue), carbon atoms (green), hydrophobic groups (grey) and rest of the C1b surface 
is colored green. The figures were created using ICM-Browser (version 3.7-2a, MolSoft 
L.L.C.). 
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Figure 9 Structures of phorbols 6-11. Functional groups that interact with the C1 domain are 
highlighted. 
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nM (for PKC), respectively.  Phorbol (10), with no acyl groups at C12 and C13, shows a Ki 
value of only 10 mM. 88 Even though the crystal structure does not confirm any interactions 
between the C13 carbonyl and the domain, it is hypothesized that the C13 carbonyl could be 
bridged via a water molecule to Met110, 89 hydrogen-bonded to Ser111 (of PKC), 90 to the 
bilayer and/or to the C9 hydroxy of 7. 82, 90 Furthermore, no interaction between the C9 hydroxy 
and the protein can be observed in the crystal structure, but it has been hypothesized that the C9 
hydroxy is also involved in interactions with the bilayer. 90 To accomplish PKC activity, the 
absolute configuration of the hydroxy-bearing carbon atom C4 in phorbol esters has to be R, the 
respective S-configuration (e.g., compound 11) provides an inactive compound. 91 In contrast, 
these 4-epimers (11) have been found to interact with the cation channel Transient Receptor 
Potential Vanilloid (TRPV4). 92, 93 However, the C4 hydroxy is not essential to provide high 
binding to PKC. 94 
The C3 hydroxy of DAG (4, Figure 5) shows the same interactions with Leu121 and Thr113 
as phorbol 13-O-acetate (7). Furthermore, the carbonyl group of the acyl moiety of DAG (4) at 
C1 has the same interaction with the protein as the C3 carbonyl of phorbol 13-O-acetate (7). 
The recently published crystal structure of PKC is that of the full-length II isoform 
complexed with adenosine 5'-(,-imido)triphosphate (AMP-PNP (12), PDB ID: 3PFQ). 69 Even 
though the crystal structure displays a modest resolution (4.0 Å), it reveals previously unknown 
interactions between the C1b domain and the catalytic domain, that produce a low activity state 
of the catalytic site (Figure 10). The kinase active site is open for substrate but, because the C1b 
domain clamps to the kinase domain, the conserved NFD-motif with the ATP-binding side chain 
of Phe629 95 is moved away from the binding site, resulting in the low activity state. 69 Upon 
membrane binding, the interactions between the C1b and kinase domains are lost and 
subsequently, the NFD-motif with the Phe629 can move back to the higher activity ATP-binding 
conformation. Indeed, Leonard et al. suggested that the NFD helix regulation of PKC is an 
alternative for the perhaps inoperative C helix mechanism of the PKCs. 69 
In addition to above-mentioned allosteric regulation by the NFD-motif and the C1b domain, 
the crystal structure reveals additional interactions between the kinase domain and the C1b 
domain (Figure 10b). 69 Residues 619-623 fill the DAG-binding site of the C1b domain and 
mimic DAG/phorbol ester binding. The C1b domain Gly124, which is hydrogen-bonded to the 
C3 carbonyl and the C4 hydroxy of phorbol esters (Figure 8), forms hydrogen bonds with the 
carbonyl of Pro619 and the amide proton of Ala621. Furthermore, the carbonyl of Ser110 forms 
a hydrogen bond with Gly623. In addition to these polar interactions, the C1b domain forms 
several hydrophobic interactions with the kinase domain, especially the C1b membrane 
penetrating side chains of residues Leu125 and Ile126 are in close contact to Phe629 of the NFD-
motif. 69 
In addition to the crystal structures of the PKC and -II C1b domains, another crystal 
structure of a C1 domain has been reported (PDB ID: 1XA6). 96 The C1 domain part of the 
uncomplexed 2-chimaerin crystal structure shows high similarities with those of the C1b 
domains of PKCII 69 and PKC. 81 Similarly as in the crystal structure of the full-length 
PKCII, 69 the N-terminal residues 27-34 of 2-chimaerin form a helix that covers the binding 
groove of the C1 domain. 96 In addition, residue Gln32 forms a hydrogen bond with Gly235 in 
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Figure 10 A) The crystal structure of the C1b domain of PKCδ complexed with phorbol 13-O-acetate 
(7, PDB ID: 1PTR) 81 superimposed on the crystal structure of the full-length PKCβII 
complexed with adenosine 5'-(β,γ-imido)triphosphate (AMP-PNP (12), 4.0 Å resolution, 
PDB ID: 3PFQ). 69 The binding pockets of the C1b domain and the ATP-binding site are 
presented as surfaces and are colored as follows: oxygen atoms (red), nitrogen atoms (blue), 
carbon atoms (green), hydrophobic groups (grey) and rest of the C1b surface is colored 
green. Phorbol 13-O-acetate (7), AMP-PNP (12) and residues are presented in ball and 
stick representation and colored by atom type. The conserved NFD-motif is colored red and 
rest of the kinase domain is colored orange. B) Side view of the PKCβII C1b domain 
(colored blue), otherwise colored as in A. Hydrogen bonds are represented as green 
spheres. The figures were created using ICM-Browser (version 3.7-2a, MolSoft L.L.C.). 
the “top” of the binding groove (Gly235 corresponds to Gly124 and Gly253 of PKCβII and 
PKCδ, respectively, see Figure 8 and Figure 10). Other proteins that contain a DAG-responsive 
C1 domain are the protein kinase D (PKD), the guanyl nucleotide-releasing proteins (RasGRPs), 
the Unc-13 scaffolding proteins, myotonic dystrophy kinase-related Cdc42-binding kinases 
(MRCK) and the DAG kinases β and γ. 97, 98 Since the number of C1 domain-containing proteins 
is considerably smaller than the number of kinases 1 and the catalytic domain and, in particular, 
the ATP-binding site of PKs is highly conserved, 99 the C1 domain provides an attractive target 
for designing selective PKC modulators. 60, 100 
 
2.2.3 Natural compounds targeting the C1 domain 
In addition to phorbol esters (5), several natural compounds target the C1 domain of PKC. 100 
Among these ligands, most bind to the C1 domain with similar interactions as the phorbol esters; 
however, there are some exceptions. The total syntheses of natural ligands are usually laborious; 
therefore, the pharmacophores of the natural ligands have been used to design simplified 
compounds, these will be presented in the next chapter (Chapter 2.2.4.). In this chapter some of 
the most important natural compounds targeting the C1 domain are presented. 
24 
 
Prostratins 
 
Prostratin (13) was initially isolated from the extracts of Homalanthus nutans G. Forst.; Guill. 
and used in traditional Samoan herbal medicine for treatment of hepatitis. 101 Prostratin (13) and 
12-deoxyphorbol 13-phenylacetate (DPP, 14) have the phorbol ester skeleton but lack the C12 
hydroxy/acyl group found in phorbols (Figure 9 and Figure 11). 102, 103 This small difference in 
the chemical structure makes these derivatives non-tumor promoters, unlike most of the phorbol 
esters. 104 Prostratin shows a Ki value of 12.5 nM for PKC. 101 In addition, prostratin derivatives 
have been suggested to be effective in HIV therapy by a PKC-dependent mechanism. 105-108 A 
five-step synthesis of prostratin and its derivatives starting from readily available phorbol (10) 
was recently published, thus facilitating the preparation of these complex structures (for 
synthetic compounds, see Chapter 2.2.4.). 102 Prostratin shows the same interactions with the C1 
domain as the phorbol esters (vide supra). 
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Figure 11 Structures of prostratin (13) and 12-deoxyphorbol 13-phenylacetate (DPP, 14). Functional 
groups that interact with the C1 domain are highlighted. 
 
Ingenols 
 
The ingenols (15 and 16) are structurally closely related to phorbol esters (5) and can be 
extracted from the sap of Euphorbia peplus L. 109 Ingenols have been used in traditional 
medicine to treat skin diseases like warts, corns and skin cancers as well as asthma and migraine. 
110, 111 Indeed, PEP005 (16) has shown promising results in the treatment of skin tumors. 111 
 
Figure 12 Structures of ingenols (15 and 16). Functional groups that interact with the C1 domain are 
highlighted. 
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When compared to the seven-membered ring of the tumor-promoting phorbol esters (5), ingenols 
(15 and 16) have an additional hydroxy group at C5 (Figure 9 and Figure 12). In addition, in 
ingenols (15 and 16) the C9 hydroxy of the phorbols is in an oxidation state of a carbonyl. 
Furthermore, the six-membered ring of the phorbols corresponds to the new seven-membered 
ring in the ingenols, where no ester groups at C12 or C13 can be found. The C3 carbonyl in the 
five-membered ring of phorbols is replaced with an acyl or hydroxy group in ingenols. These 
differences in the structures of the corresponding ingenols make them more hydrophilic than the 
phorbol esters; for example, the clogP values of PEP005 (16) and PMA (6) are 3.89 and 6.65, 
respectively. 112 
Ingenol (15) binds more tightly than phorbol (10) to PKC (Ki values of 30 μM and 10 mM, 
respectively). 88, 113 PEP005 (16), 114 with an (Z)-2-methylbut-2-enoyl group at C3, shows Ki 
values of 0.1-0.4 nM, depending on the PKC isoform studied. 112 Despite the lack of specificity 
among isoforms, PEP005 (16) activates PKC more potently than PKC in vitro. While PMA (6) 
induces the translocation of PKC to the plasma membrane, PEP005 (16) induces an initial 
translocation of the enzyme from the cytosol to the nuclear and perinuclear membranes. 112, 115, 
116 
 
 
Bryostatins 
 
The bryostatins (e.g. 17 and 18) were first isolated from the marine bryozoan Bugula neritina L.; 
117 however, the symbiont bacteria are thought to be the actual sources of the compounds. 118 
There are at least 20 naturally occurring bryostatins that bind to the regulatory domain of PKC 
with high affinity. 119 Bryostatin 1 (17), the most extensively examined bryostatin, and bryostatin 
2 (18), show Ki values of 1.35 and 5.9 nM, respectively, for PKC. 120 Bryostatins have 
proceeded to clinical trials as potential treatment for different cancers, AD, and also acting as 
activators of effector cells of the immune system. 33, 100 The highly complex structures of the 
 
 
Figure 13 Structures of representative examples of bryostatins (17 and 18). Functional groups that 
interact with the C1 domain are highlighted. The Ki (nM) values are also shown. 
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bryostatins make the total synthesis laborious; generally over 40 linear synthesis steps are 
required. 119, 121, 122 However, simplified derivatives of the bryostatins have been synthesized (see 
Chapter 2.2.4.). 
The bryostatins bind to the regulatory domain in the same way as phorbol esters (5). 
Functional groups which are involved in forming hydrogen bonds with the C1 domain are the 
carbonyl of C1 and the hydroxy of C19 and C26 (Figure 13). Bryostatin 1 (17) competes for 
binding with DAG and phorbol esters. However, specific to bryostatin 1 (17) is that the phorbol 
ester antagonism, at least for leukemia cell differentiation, is non-competitive 123 and it shows 
biphasic concentration-dependent effects in many biological responses. 100 Furthermore, 
bryostatin 1 (17) functions as an activator and induces translocation of PKC almost exclusively 
to the nuclear membrane. 56 
 
 
Aplysiatoxins 
 
The marine spiroketals aplysiatoxin (19a) and debromoaplysiatoxin (19b, Figure 14) can be 
isolated from the sea hare Stylocheilus longicauda Quoy & Gaimard. 124 These structurally 
complex spiroketals compete with [20-3H]phorbol 12,13-dibutyrate ([3H]PDBu) for binding to 
its receptors 125 but are tumor-promoters. 126 Interestingly, compound 19a was shown to inhibit 
[3H]PDBu binding in cloned rat embryo fibroblast (CREF) cells more strongly than compound 
19b (IC50 values of 14 and 94 nM, respectively); however, the bromine in the phenol ring caused 
also higher tumor-promoting activity. 125 The measured Ki values for 19a and 19b are 3.0 nM 127 
and 20 nM, 128 respectively, for PKC. 
 
Figure 14 Structures of aplysiatoxins (19a and 19b). Functional groups that interact with the C1 
domain are highlighted. 
Indolactams 
 
Among the indolactams, the teleocidin family of indole alkaloids was first isolated from 
Streptomyces mediocidicus Labeda; Wellington et al. 129 These teleocidins are tumor 
promoters 130 and bind to the C1 domain. 131 The structurally simplest indolactam is (-)-
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indolactam V (20), which is considered to be the minimum-sized structure exhibiting tumor-
promoter activity. 132 Indolactam V (20) and teleocidin B-4 (21) show Ki values of 80 and 0.4 
nM, respectively, for PKC. 133 The discovery of the indolactams has led to the development of 
synthetic indo- and benzolactam derivatives, these will be discussed in more detail in Chapter 
2.2.4. 
The indolactams bind to the C1b domain of PKC in a similar way as the phorbol esters (5). 
134, 135 The primary hydroxy groups of indolactams form hydrogen bonds to Thr113 and Leu121 
in the groove of the PKC C1b domain (Figure 15, residue numbering corresponds that of 
PKCII, see Figure 8). In addition, the lactam N-hydrogen is hydrogen-bonded to Leu121 and 
the C11 carbonyl group acts as a hydrogen bond acceptor for Gly124. Furthermore, the indole 
rings of indolactams are thought to have CH/ interactions with Pro112 of PKC. 136 
 
Figure 15 Structures of indolactam (20) and teleocidin B-4 (21). Functional groups that interact with 
the C1 domain are highlighted. 
Anthracyclines 
 
Anthracyclines, such as doxorubicin (DOX, 22) and daunorubicin (daunomycin (23), Figure 16), 
are chemotherapeutic agents that are obtained from Streptomyces peucetius Grein et al. and S. 
coeruleorubidus Preobrazhenskaya; Pridham et al. 137, 138 Doxorubicin (22) has been used in the 
clinic for more than 30 years and remains one of the most widely used cancer chemotherapeutics. 
139 However, tumor cells are able to develop resistance to doxorubicin (22). Fortunately, 
synthetic derivatives have been developed to overcome this setback (see Chapter 2.2.4.). 
Doxorubicin (22) does not effectively bind PKC (< 20% inhibition of [3H]PDBu at 20 μM) 
and localizes in the nucleus. 139 The anthracyclines exert their antitumor effects mainly via 
interference with a DNA-topoisomerase II interaction during DNA replication. 140 Doxorubicin 
(22) intercalates into DNA with rings B and C between the adjacent base pairs of DNA and the 
aminoglycoside moiety located in the minor groove of DNA. 138 This stabilizes the DNA-
topoisomerase complex, and the DNA replication and cell division are halted. However, when 
the 3´-amino group of the daunosamine aminoglycoside is substituted with, for example, a 
benzyl group, and more importantly, the C14 hydroxy group of 22 is acylated, the new derivative 
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binds DNA only weakly and PKC activity can be obtained instead. 139 The synthetic 
anthracyclines are further discussed in Chapter 2.2.4. 
 
Figure 16 Structures of anthracyclines (22 and 23). Functional groups that interact with the C1 domain 
are highlighted. 
 
Calphostins 
 
The calphostins (e.g. 24 and 25) are polycyclic aromatic perylenequinones and potent PKC-
selective inhibitors isolated from the fungus Cladosporium cladosporioides Fresenius; de  
Vries. 141, 142 Of the calphostins, the best binding affinity to PKC can be obtained by calphostin C 
(24). It selectively binds the C1 regulatory domain of PKC, showing an IC50 value of 50 nM for 
rat brain PKC isoenzymes, when the IC50 values for example PKA and polyphosphate kinase 
(PPK) are greater than 100 μM. 141, 143 Interestingly, the inhibitory effects of calphostin C (24) 
include both the inhibition of phosphotransferase activity and the inhibition of phorbol ester 
binding to the C1 domain. 141, 144 The activities of the calphostins are light-induced, making them 
candidates for photodynamic therapeutics. 145-147 
 
 
No molecular modeling results of calphostin C (24) docked to the C1 domain can be found in 
literature. On the other hand, one could assume that the calphostins bind to the C1 domain in a 
similar way as the structurally related anthracyclines (vide supra). The total syntheses of natural 
compounds are usually laborious and this is also the case with the calphostins; the present total 
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synthesis of calphostin C (24) requires 12 steps. 148, 149 Derivatives of calphostins have been 
synthesized, see Chapter 2.2.4. 
Although calphostin C (24) has been reported to show proapoptotic effects in numerous 
cancer cell lines 150-152 and it has been suggested as a candidate for photodynamic cancer 
therapy, 147, 153 there are few or no reports describing the effects of calphostin C (24) on in vivo 
models of cancer.  
 
 
Iridals and SJ23B 
 
The iridal type triterpenoids can be obtained from sword lilies (e.g. Iris tectorum Maxim. and I. 
germanica L.) and bind to the C1 domains and activate PKC. 154, 155 Two iridals (26 and 27, 
Figure 17) were shown to bind to PKC with Ki values of 84 and 76 nM, respectively, and with 
slightly better binding affinities (Ki values of 42 and 16 nM, respectively) for Ras guanyl-
releasing protein 3 (RasGRP3). 156 The iridals have shown anti-tumor activity in several cell 
lines and in some cases to be less affected by multi-drug resistance expressing cell lines than 
doxorubicin (22) or paclitaxel. 157 Recently, the first total synthesis of an iridal (28) was 
performed, requiring over 20 steps. 158 
 
Figure 17 Structures of iridals (26-28) and SJ23B (29). Functional groups that interact with the C1 
domain are highlighted. 
A jatrophane diterpene SJ23B (29, Figure 17) isolated from Euphorbia semiperfoliata Viv. 159 
has shown in vitro potential PKC-mediated antiviral effects on HIV-1 infection and activation 
of latent HIV-1 gene expression, being 10-fold more potent than prostratin (13). 160 Furthermore, 
it is not toxic and it does not induce cell transformation, suggesting that it lacks tumor-promoting 
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activity. So far, no PKC-binding data has been provided. Studies with other jatrophane 
diterpenes revealed the importance of the acetoxy groups at C2 and C15 for activity in HIV-1 
models. 160 
 
 
Bistramide A 
 
Bistramide A (bistratene A, 30) is a bioactive cyclic polyether initially isolated from the marine 
ascidian Lissoclinum bistratum Sluiter in 1988 by Verbist et al. 161 Six years later four additional 
members of the family were isolated. 162 This class of compounds shows important cyto- 163 and 
neurotoxicity, 164-166 for example IC50 values of bistramide A (30) for the human-derived A549 
lung and MCF-7 breast adenocarcinoma cells were between 1.0 and 2.9 nM. 167 Bistramide A 
(30) has been shown to have a short half-life in cell culture medium; only 2.8 hours. 167 The 
bistramides also show antiparasitic 168, 169 and immunomodulatory activities, 163 and they play a 
complex role in cell cycle regulation, differentiation, and apoptosis, thus have emerged as a 
potential anti-inflammatory and anti-tumor agents. 162 
 
 
Bistramide A (30) was initially found to activate PKC in human leukemia (HL)-60 and MM96E 
cells. 163, 170, 171 More recently, covalent modification of actin and disruption of filamentous actin 
were reported as the major mode of action for bistramide A (30) in various cancer cell lines. 172 
The Ki value of bistramide A (30) for PKC was found to be only 28 μM. In contrast, the 
dissociation constant (Kd) value of bistramide A (30) for actin was determined to be 6.8 nM. 
Hence, there has been little consensus on the activation of PKCδ: bistramide A (30) does not 
activate PKCδ in vitro, nor does it compete with phorbol esters in binding to the C1 domain. 167, 
172, 173 However, while bistramide A (30) failed to translocate green fluorescent protein (GFP)-
PKCδ in rat basophilic leukemia (RBL) cells, 172 immunostaining and fractionation studies 
showed migration of PKCδ to the perinuclear region rather than the nuclear or plasma 
membrane. 170 Furthermore, only specific substrates of PKCδ were phosphorylated, suggesting 
an atypical mode of activation. 174 
In 2004, Kozmin et al. performed the first total synthesis of bistramide A (30). 175 Since then, 
the research groups of Crimmins, 176 Panek, 177, 178 and Yadav 179 have synthesized bistramide A 
(30) with a longest linear sequence of 18 steps. The crystal structure of actin complexed with 
bistramide A (30) was published in 2006 (PDB ID: 2FXU). 180 The crystal structure helped 
researchers to develop simplified analogs of bistramide A (30) and to perform SAR studies. 173, 
181 Bistramide C is another member of the bistramide family, which has been synthesized. 182, 183 
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Summary of the natural compounds targeting the C1 domain 
 
Several natural compounds show very potent binding to the C1 domain of PKC (e.g. bryostatin 1 
(17) and PEP005 (16)), however, the resulting biological outcomes of the ligands are more 
important than only the inhibitor dissociation constant. For example, while the indolactam 
teleocidin B-4 (21) shows impressive binding of PKC (Ki of 0.4 nM), it is also a tumor-
promoter. 130 In contrast, although prostratin (13) is a non-tumor promoting PKC ligand, it 
exhibits possible cytotoxic properties. 108 Furthermore, bryostatin 1 (17) shows impressive 
antineoplastic properties but it has not shown to be efficient enough as a single agent in clinical 
trials. 184, 185 One promising natural compound is PEP005 (16), which has shown to be potent in 
topical treatment of actinic keratosis and will probably reach the market in the near 
future. 111, 186, 187 
Even though C1-domain-binding compounds can be obtained from natural sources, the 
isolated yields of the compounds are usually very low. In addition, the compounds show often 
highly complex structures and hence, the total syntheses of the compounds are often laborious. 
Nevertheless, the studies of the natural compounds have yielded valuable pharmacophores, 
which have been used to develop simplified analogs of the natural compounds. 
 
2.2.4 Synthetic compounds targeting the C1 domain 
 
Natural compounds targeting the C1 domain can generally be obtained in small quantities from 
natural sources. Even though biotechnological methods have been used in some cases to produce 
larger quantities of active compounds, synthetically prepared compounds could enhance the 
effectiveness of the production and the development of improved derivatives. However, since 
natural compounds often show complex structures, the total syntheses are generally laborious. In 
fact, many synthetic compounds targeting the C1 domain are semisynthetic, that is, a natural 
compound has been used as a starting material for the derivatives. In addition, the 
pharmacophores of the natural compounds have been used to develop derivatives with simplified 
structures. Rational design has also been used in preparing totally unique C1-targeting 
compounds. In this chapter, some of the most important synthetic compounds targeting the C1 
domain are presented. 
 
 
Prostratin analogs 
 
The complex structure of prostratin (13, Figure 11) has been one of the reasons why prostratin 
based compounds of this non-tumor-promoting ligand have not been developed. However, 
Wender et al. recently published a five-step synthesis of prostratin (13), DPP (14) and the 13-O-
ether analogs 31 and 32 starting from readily available phorbol (10) (Figure 9 and Figure 18). 102 
Examples of prostratin analogs synthesized since then are 33-35 and these were shown to bind to 
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a mixture of PKC isoforms, e.g. the Ki value of analog 33 was 1.6 nM. 188 The analogs 33-35 
also showed activity against the human leukemia cell line K562, EC50 values ranging between 
0.02-0.03 nM. In addition, compounds 33-35 induced the expression of HIV in cells with latent 
viral expression. 
 
Figure 18 Structures of prostratin analogs (31-35). Functional groups that are thought to interact with 
the C1 domain are highlighted. 
 
Ingenol derivatives 
 
The 3-O-tetradecanoyl (36) 189 and 3-O-benzoyl (37) 190 derivatives of ingenol are semisynthetic 
compounds which have been prepared starting from ingenol (15) (Figure 12 and Figure 19). The 
derivative 37 shows a Ki value of 0.14 nM for PKC. 190 The Ki value for 36 is 7 nM but the 
value cannot be compared to the Ki value of 37 since it was measured in vitro by release of 
[3H]phorbol 12,13-dipropionate bound specifically to mouse epidermal particulate fraction. 191 
However, 36 and 37 were found to be tumor-promoting. Interestingly, a dibenzoate derivative 
(38, Ki = 240 nM for PKC) 190 was found to induce apoptosis in Jurkat cells, however, not via 
PKC-mediated activation, but via caspase-3 activation. 192 The fact that induction of apoptosis is 
not via PKC is not surprising, since 38 cannot form the same interactions with the groove in the 
binding site of the C1 domain as is seen for 36 because of its C20 benzoate group. Another 
diester (PEP008, 39) has showed permanent growth arrest in solid tumor (melanoma, breast, and 
colon) cell lines. 193 
 
Figure 19 Structures of synthetic ingenol derivatives (36-39). Functional groups that are thought to 
interact with the C1 domain are highlighted. 
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Bryostatin analogs 
 
The naturally occurring bryostatins show high affinity for the C1 domain of PKC, 119 however, 
the total syntheses of these highly complex macrocyclics require generally over 40 linear steps. 
119, 121, 122 In addition, results from clinical trials of bryostatins as single agents 184, 185 or in 
combination therapy with established cancer drugs 194-201 have been rather disappointing. 
Therefore, research groups have put on an effort into reducing the required steps for total 
synthesis as well as developing analogs of bryostatins. 119 The Wender group developed a 
synthesis route for simplified derivatives (40-44) of bryostatin 1 (17) with a significantly reduced 
number of reaction steps. 202, 203 Removal of the methyl substituent at C26 of compound 40 (Ki 
value of 3.4 nM for rat brain PKC isoenzymes) 204 gave compound 41, 120 which showed higher 
affinity (Ki value of 0.25 nM for rat brain PKC isoenzymes), as predicted by the pharmacophore 
of phorbol esters (Figure 9). Interestingly, the addition of an acetoxy substituent to C7, similar to 
bryostatin 1 (17), reduced the Ki value to 13 nM (compound 42), and the addition of a hydroxy 
group to C7 (analogs 43 and 44) reduced the binding affinity even further by three to four orders 
of magnitude. On the other hand, bryostatin 2 (18), with a hydroxy group at C7, shows only a 
slight reduction in binding affinity compared to bryostatin 1 (17, see Chapter 2.2.3.). 120 
Alternatively, compound 45 (see Figure 13; R1 = H, R2 = H, R3 = Ac, R4 = Me), which has a C7 
acetoxy group as bryostatin 1 (17) and analog 42, but lacks the C30 methoxy carbonyl group 
found in bryostatin 1 (17), exhibited a reduced Ki value of 0.52 nM for PKC but is also a 
functional antagonist of PMA (6). 205 It has been speculated that these differences in binding 
affinities are due to the C8 gem-dimethyl groups found in the natural bryostatins (e.g. bryostatin 
1 (17)), which are able to shield a polar C7 substituent. Furthermore, the C3 hydroxy group of 
bryostatins is pivotal for high binding affinity. 204 For further SAR information, see reviews in 
ref. 100 and 119. 
 
Figure 20 Structures of synthetic bryostatin analogs (40-44). Functional groups that are thought to 
interact with the C1 domain are highlighted. The Ki values are also shown. a Wender et al. 
also reported a Ki value of 3.1 nM for the same derivative. 206 
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Aplysiatoxin analogs 
 
The natural aplysiatoxins 19a and 19b bind to PKC with high affinity but are tumor-promoting 
compounds. 125 Recently, Nakagawa et al. speculated that the bromine present in the natural 
aplysiatoxin 19a, as well as the hydrophobicity of the compound, produces the tumor-promoting 
activity. 127 Indeed, Nakagawa et al. synthesized a structurally simpler aplysiatoxin analog (46) 
with bryostatin-like activity, which showed a Ki value of 15 nM to PKC (the Ki value of 19a is 
3.0 nM). 127 Removal of the phenolic hydroxy group from 19a gave compound 47, which 
showed an even more reduced binding affinity (Ki of 400 nM for PKC), suggesting that the 
geminal dimethyl group and/or the phenolic hydroxy group of analog 46 specifically interact 
with PKC. Furthermore, compound 46 functions as a PKC activator but does not induce 
translocation of the enzyme only to the plasma membrane but also to the nuclear membrane, 127 
which could be an indication of a non-tumor-promoting modulator. 56 The synthesis of analog 46 
requires 22 steps. 127 
 
Figure 21 Structures of synthetic aplysiatoxin analogs (46 and 47). Functional groups that are thought 
to interact with the C1 domain are highlighted. 
 
Indo- and benzolactams 
 
The natural indolactams 20 and 21 are tumor-promoting compounds but bind with high affinity 
to PKC (e.g. 20 shows a Ki of 80 nM for PKC, cf. 2.2.3.). 133 Endo et al. introduced the 
benzolactams as a result from research into the active structure of teleocidin (21). 207 
Benzolactam 48 showed a decreased binding affinity towards PKC (Ki of 1700 nM), however, 
compound 49, with a lipophilic side chain at C9, showed an improved Ki value of 1.8 nM 
(PKC). In addition to the above-mentioned compounds, several research groups have prepared 
synthetic benzo- (e.g. 48-55) and indolactams (e.g. 56-57) and have revealed important SARs 
(see, e.g. ref. 100, 133, and 208-210). Many of these compounds show improved selectivity 
profiles compared to the natural indolactam family of compounds. 100, 135, 208, 211-214 The 
benzolactam derivatives have been studied for their antiproliferative effects on cancer cells, 133, 
207, 211, 215 and their neuroprotective effects in cell-based models of AD. 216 The indolactam 20 
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and several benzolactam derivatives (e.g. 49) have been reported to inhibit the proliferation of 
HL-60 leukemia cells. 133, 207, 215 
The benzolactams bind to the regulatory domain of PKC (Figure 8) with the same 
interactions as the indolactams (see Chapter 2.2.3.) but do not have CH/ interactions with 
Pro112 of PKC (Figure 15 and Figure 22, residue numbering corresponds to PKCII). 
 
Figure 22 Structures of synthetic benzo- (48-55) and indolactams (56 and 57). Functional groups that 
are thought to interact with the C1 domain are highlighted. 
 
Anthracyclines 
 
To overcome doxorubicin (22) resistance and to reduce doxorubicin-induced cardiotoxicity, a 
novel semisynthetic anthracycline derivative AD 198 (58) was prepared. 217 It only weakly binds 
to DNA and has little inhibitory activity on topoisomerase II, suggesting that it has a different 
mechanism of action than conventional anthracyclines. 140 AD 198 (58) activates PKC 218 by 
targeting the C1 domain 219 but shows a modest Ki value of 2.5 M for PKC. 219 However, AD 
198 (58) is effective in vitro against several cancer cell lines 220-223 and its anti-tumor activity is 
superior to doxorubicin (22). 224 
By using the crystal structure of the PKC C1b domain, 81 three theoretical binding models 
were proposed in which AD 198 (58) binds to the C1 domain. 219 In these models, AD 198 (58) 
binds in the groove of the C1b domain but less deeply than phorbol esters (5) and with different 
interactions (Figure 24A). In one of the binding models of AD 198 (58), Ser111 (residue 
numbering corresponds to that of the crystal structure of full-length PKCII) 69 and Gln128 bind 
to the C9 hydroxy and Gly124 binds to the C12 carbonyl and C11 hydroxy, which is also 
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Figure 23 Structures of synthetic anthracyclines (58-63). Functional groups that are thought to interact 
with the C1 domain are highlighted. 
hydrogen-bonded to Leu121 (Figure 23 and Figure 24B). The C14 valerate and C3´ N-benzyl 
group were thought to play a similar role to the acyl groups of phorbol esters (5) in binding to C1 
domains (Figure 8), and the positively charged amino group was suggested to be at least partially 
responsible for the translocation to the nuclear membrane. Furthermore, the valerate group of 
AD 198 (58) increases the lipophilicity compared to doxorubicin (22) and induces AD 198 (58) 
to localize in the perinuclear region. 225 
 
Figure 24 One of the suggested binding models of AD 198 (58) to the C1 domain. 219 A) AD 198 (58) 
docked to the C1b domain of PKC. B) A binding model of AD 198 (58) in the C1b domain 
of PKC showing hydrogen bonds to the residues (black lines). Residue numbering 
corresponds to that of the crystal structure of full-length PKCII. 69 AD 198 (58) and the 
residues are presented in stick representation and are colored by atom type. Adapted with 
permission from ref. 219. Copyright 2011 American Chemical Society. 
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Among different C14 acyl-substituted derivatives synthesized, compounds containing 4-5 
carbons (e.g., AD 198 (58), AD 444 (59) and AD 445 (60)) were found to be the most promising. 
139 Interestingly, doxorubicin (22) and AD 288 (61), the principal metabolite of AD198 (58), are 
both incapable of inhibiting PKC activity or competing for [3H]PDBu binding. 139 
Another semisynthetic anthracycline derivative, valrubicin (AD 32, 62), 221 has similar PKC-
inhibitory properties to AD 198 (58), 226 and the mechanism of action of its valerate-free 
metabolite AD 41 (63) can be compared to that of AD 288 (61) and doxorubicin (22). 225 
Valrubicin (62) was reported to be safe in a phase I trial with advanced gynecological 
malignancies 227 and has thereafter been approved in the US for topical treatment of bladder 
cancer. 140 
 
 
Calphostin analogs 
 
Morgan and co-workers used ent-pleichrome (64, an atropisomer of calphostin D (25)) and the 
crystal structure of the PKC C1b domain 81 to design new perylenequinone derivatives. 228 The 
docking studies showed an unfilled hydrophobic pocket in the protein, where the C2,C2´-
methoxy groups were pointing; thus, the corresponding bisisopropyl and bis-n-propyl derivatives 
(compounds 65 and 66, respectively) were synthesized. Both compounds showed increased 
binding affinities to rat brain PKC isoenzymes compared to 64 (IC50 values of 0.8, 1.5 and 3.5 
M, respectively), however, higher values than for the natural calphostin C (24, IC50 = 0.05 μM). 
Among the natural calphostins, higher binding affinities can be obtained with more hydrophobic 
groups at C7 and C7´. 143 Substitution of the 2-hydroxypropyl groups at C7 and C7´ (R2 in 64) 
with n-propyl groups resulted in better binding. 228 The obtained IC50 value of derivative 67 was 
0.4 M. Furthermore, 16- to 28-fold higher binding affinities could be obtained with the M-
atropisomers compared to the P-atropisomers. 
No binding interaction data can be found in the literature. On the other hand, one could 
assume that the calphostins bind to the C1 domain in a similar way as the structurally related 
anthracyclines (vide supra). 
 
 
DAG-lactones 
 
The Blumberg and Marquez groups used endogenous DAG (4) as a starting point in the design of 
DAG-lactones (e.g. 68-71). 60, 229 Their plan was to design conformationally constrained -
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lactones to overcome the entropial penalty caused by the flexible structure of DAG (4) upon 
binding to the C1 domain. 60, 229 To improve the interactions with the conserved hydrophobic 
amino acids in the space between the two β-sheets of the C1 domain (Figure 8), the acyl and 
alkylidene groups were substituted with various lipophilic side chains (Figure 25). 230 
Subsequently, the potency of the DAG-lactones was increased to Ki values as low as 1.45 nM 
(enantiomer (2R)-68, PKC). 231 Synthesis of the optically pure (2R)-DAG-lactones (the active 
enantiomers) 229, 231 requires 11 linear steps, significantly fewer than the number of synthesis 
steps required for many of the natural compounds (see Chapter 2.2.3.). 231 
 
Figure 25 Structures of synthetic DAG-lactones (68-71). Functional groups that are thought to interact 
with the C1 domain are highlighted. 
Molecular modeling studies performed on the DAG-lactones reveal two competing binding 
modes to the C1 domain (Figure 26). 89, 230 In the “sn-1” mode, the acyl group carbonyl of 
lactone 69 is hydrogen-bonded to Gly253 of the C1 domain, and the alkylidene group is pointing 
towards the lipid membranes (residue numbers correspond to that of the C1b domain of PKC, 
see Figure 26). The hydroxy group is hydrogen-bonded, as the C20 hydroxy group of phorbol 
esters (5), to Thr242 and Leu251. In the “sn-2” mode, the lactone carbonyl is hydrogen-bonded 
to Gly253 and the alkyl chain of the acyl group is pointing towards the lipid membranes. Again, 
the hydroxy group is hydrogen-bonded to Thr242 and Leu251. 
Several DAG-lactones show some PKC isoenzyme selective binding; 232, 233 however, 
differences in binding do not necessarily translate into differences in the potency to induce 
biological effects. 59 Nevertheless, a striking binding selectivity of compound 70 between the 
individual C1 domains of the PKC isoforms was observed: the Ki values of the isolated C1a and 
C1b domains of PKC were 2780 and 1.78 nM, respectively, and the Ki values of the C1a and 
C1b domains of PKC were 610 and > 10000 nM, respectively. 233 On the other hand, DAG-
lactone 70 showed only modest selectivity between the whole isoforms. For SAR studies of 
DAG-lactones, please see ref. 100 and 229. 
Several DAG-lactones have shown antiproliferative and proapoptotic activity, e.g. 68 234 and 
(2R)-68 235 exhibited proapoptotic activities in lymph node carcinoma of the prostate (LNCaP) 
cells. The DAG-lactones 68 and 71 have also shown to be active in HIV-1 eradication in ex vivo 
culture experiments. 236 
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Figure 26 The binding modes of DAG-lactone 69 to the C1b domain of PKCδ: “sn-1” (left) and “sn-2” 
(right). 230 Residue numbering corresponds to that of the crystal structure of the C1b domain 
of PKCδ, 81 the corresponding PKCβII residue numbers are (in parenthesis): Gly253 
(Gly124), Leu251 (Leu121) and Thr242 (Thr113). DAG-lactone 69 is presented in stick 
representation, the residues in ball and stick representation, and are colored by atom type. 
Hydrogen bonds are shown with yellow dotted lines and the respective distances showed in 
ångströms (Å). Reprinted with permission from ref. 230. Copyright 2011 American Chemical 
Society. 
Summary of the synthetic compounds targeting the C1 domain 
 
The complex chemical structures and the lack of availability of compounds targeting the C1 
domain of PKC from sensitive ecosystems such as oceans and seas have been driving forces in 
the development of structurally simplified analogs of the natural compounds. Indeed, a recently 
published five-step synthesis of prostratin (13) and its analogs opens a new opportunity in the 
development of improved prostratin analogs with reduced toxic properties. 102, 188 
Extensive research has also been performed in simplifying the chemical structure of the 
natural bryostatins. 100 By using the pharmacophores of phorbol esters, newly designed 
compounds showed increased binding affinities while the required reaction steps of the synthesis 
route were significantly reduced. 202, 203 Indeed, synthetic analogs of bryostatin may provide the 
answer to overcome the inefficacy issues faced in clinical trials of bryostatin 1 (17). 184, 185 The 
aplysiatoxin analogs are other macrocyclic lactones that are products from structure 
simplification of the natural counterparts and show indications of non-tumor-promoting 
modulators. 56, 127 
The indo- and benzolactams have also provided evidence to be potential future drug 
candidates against cancer and AD. 133, 207, 211, 215, 216 However, more in vivo studies are needed to 
validate these compounds. 
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Another class of interesting C1 domain-targeted compounds is the DAG-lactones. Research into 
these structurally constrained DAG analogs has not only provided high binding compounds 231 
but also important information of the correlation between ligand structure and the biological 
response of PKC. 59 On the other hand, more in vivo tests of these DAG-lactones are needed to 
validate them as potent drug candidates. 
2.3 Anaplastic lymphoma kinase 
ALK is a RTK, which is comprised of an extracellular ligand-binding domain, a putative 
transmembrane domain and a cytoplasmic tyrosine kinase domain (Figure 27). 31 Among the 
RTKs, the extracellular domain of ALK is most similar to that of leukocyte tyrosine kinase 
(LTK), 28 which is a member of the superfamily of insulin receptors (IRs). 
 
Figure 27 The structure of anaplastic lymphoma kinase. MAM (meprin-A5 protein-receptor protein 
tyrosine phosphatase ), LDL-A (low-density lipoprotein class A), G-rich (glycine-rich) and 
TM (transmembrane domain). 
The natural ligand of ALK is still to be found, hence, ALK is an orphan receptor. The growth 
factors pleiotrophin (PTN) 237 and midkine (MK) 238 have been suggested as natural ALK 
ligands, however, there is a high level of debate about this. 31, 239, 240 ALK is also a dependence 
receptor, 241 that is, ALK can exert opposite cellular effects depending on the absence or 
presence of a ligand. 239, 242 In the absence of a ligand, the kinase is inactive and ALK is 
enhancing apoptosis. However, in the presence of a ligand the kinase is active and apoptosis is 
decreased; this is also true in the constitutively activated fusion products of ALK (vide infra). 
When ALK is unligated, the cleavage of ALK by caspases exposes an intracellular and 
proapoptotic juxta-membrane domain of ALK, which facilitates apoptosis. 243 Ligands used to 
demonstrate these phenomena were agonist anti-ALK antibodies. 244 
Although the function of the full-length ALK receptor is still poorly known, it has been 
shown that ALK plays an important role in the development of the central and peripheral 
nervous system. 30 ALK expression is restricted to rare scattered neural cells 245 and recent data 
suggest that ALK is involved in neuronal cell differentiation and regeneration, synapse formation 
and muscle cell migration. 31 Despite ALK having a role in development and expression patterns, 
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ALK-deficient mice appear normal and display no visible tissue abnormalities. 246 However, 
ALK can be aberrantly activated as a result of a (2;5)(p23;q35) chromosomal translocation in 
ALCLs. 247, 248 In most cases, the translocation causes the fusion of the intracellular catalytic 
domain of ALK to the oligomerization domain (OD) of nucleophosmin (NPM, vide infra). The 
resulting NPM-ALK fusion product has constitutive kinase activity and is highly oncogenic. 32 
Several additional fusion partners that have dimerization domains have also been described. 31, 
249 Oncogenic mutants or fusion variants of ALK have also been identified in neuroblastomas, 
inflammatory myofibroblastic tumors and diffuse large B-cell lymphoma. 31 Furthermore, the 
echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene was recently 
discovered to be expressed in a subset of non-small cell lung cancers (NSCLCs), breast and 
colorectal cancers. 250, 251 
Sixty to eighty percent of ALCLs are ALK-positive; and seventy to eighty percent of ALK-
positive ALCLs express the NPM-ALK fusion protein. 252 Children and young adults are more 
likely to be affected by these tumors and with a slight male predominance, accounting for 
approximately 20-40% of non-Hodgkin lymphomas (NHL) in children and < 5% of all 
cases. 253, 254 
 
2.3.1 Structure, activation and regulation 
 
Structure – the wild type enzyme 
 
The domain organization of ALK is conserved throughout evolution, with the kinase domains 
showing the highest similarities between species. 240 Mouse (m) and human (h) ALK show 87% 
overall homology at the protein level, and within the kinase domain these differ at only four 
amino acids. Compared to mALK, hALK contains one extra tyrosine residue, Tyr1604, which 
has been implicated in tumor progression. 243 
Among RTKs, ligand-binding to the extracellular domain induces activation of the kinase on 
the cytoplasmic side, which initiates the intracellular signaling. 255 Also the hALK consists of an 
extracellular ligand-binding domain, a putative transmembrane (TM) domain and a cytoplasmic 
kinase domain (Figure 27). 30, 31 In the extracellular domain there is an N-terminal signal peptide, 
two meprin-A5 protein-receptor protein tyrosine phosphatase  (MAM) domains, one low-
density lipoprotein class A (LDL-A) domain and a glycine-rich (G-rich) region. 240 Within ALK, 
the LDL-A domain has an unknown function. However, in the low-density lipoprotein (LDL) 
receptor, this domain is involved in binding to LDL, 256, 257 suggesting a potential role in ligand-
binding for this domain of ALK. The importance of the MAM domains for ALK function is also 
unclear. Interestingly, ALK is the only RTK known to date that have MAM domains. 258 MAM 
domains comprise about 160 amino acids that are present in transmembrane proteins such as the 
meprins and receptor protein-tyrosine phosphatases, where they are thought to function in cell-
cell interactions. 259, 260 The importance of the MAM domain in Drosophila ALK (dALK) was 
showed by a point mutation of a highly conserved aspartic residue; an arginine residue at that 
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position gave an inactive dALK. 261 The third extracellular domain, the G-rich region, also seems 
to have a functional significance in ALK. 261 Again, point mutations that convert a single glycine 
residue within the G-rich region into an acidic amino acid showed inactive dALK mutants. 
The TM domain connects the extracellular domain with the kinase intracellular domain 
(Figure 27). 30, 262 This putative TM domain consists generally of 28 hydrophobic amino acids, 
consistent with a membrane-spanning segment. In addition, the TM domain is flanked on its 
cytoplasmic side by basic amino acid residues typical of the junction between transmembrane 
and cytoplasmic domains. 
The intracellular region contains the kinase domain. The kinase domain will be discussed in 
more detail in Chapter 2.3.2. At the C-terminus of ALK, the phosphotyrosine-dependent binding 
site for the substrate protein Scr (sarcoma) homology 2 domain-containing (SHC) can be found. 
263, 264 In addition, an interaction site for the phosphotyrosine-dependent binding of PLC- can 
also be found in the intracellular region of ALK. 243, 264 PLC- is involved in the generation of 
DAG and IP3, which are involved in the activation of PKC (see Chapter 2.2.1). 
 
Structure – the fusion proteins 
 
As a result of the (2;5)(p23;q35) chromosomal translocation, ALK can be unexpectedly 
activated. 247, 248 In most cases, the translocation causes the fusion of the intracellular catalytic 
domain of ALK to the OD of NPM (Figure 28), but several additional fusion partners that have 
dimerization domains have also been described. 31, 249 For example, the EML4-ALK fusion gene 
was recently discovered. 250, 251 
 
Figure 28 Structures of nucleophosmin (NPM), anaplastic lymphoma kinase (ALK) and the NPM-ALK 
fusion product. 
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The NPM-ALK fusion product does not have the TM domain and the extracellular domains of 
ALK (Figure 28), and the fusion product of NPM-ALK is cytosolic or nuclear. 265, 266 However, 
it is the fusion partner and not the kinase part of ALK in the homo- or heterodimers of the fusion 
products which determines the distribution of the fusion products (Figure 29). For example, in 
the case of the heterodimer of the NPM-ALK fusion product, NPM contains the nuclear 
localization signals but these cannot be found in the homodimer of the fusion product. Hence, the 
heterodimer is distributed in the nucleus and the homodimer is distributed in the cytosol. In 
contrast, both the hetero- and homodimers of the fusion products of tropomyosin -3 (TPM3) 
and ALK are distributed in the cytosol since TPM3 does not contain a nuclear localization signal. 
 
Figure 29 Distribution of hetero- and homodimers of fusion products of ALK in the cells. A) NPM-ALK 
and B) TPM3-ALK. ALK (anaplastic lymphoma kinase); NLS (nuclear localization signals); 
NPM (nucleophosmin); TPM3 (tropomyosin -3). 
Activation 
 
The full length WT ALK expression decreases rapidly after birth and is maintained at low levels 
in adults. 240 However, dimerization of the NPM-ALK fusion product stimulates the 
autophosphorylation of the ALK catalytic domain 267, 268 and, subsequently, phosphorylation of 
other tyrosine residues in NPM-ALK resulting in activation. 269 Alternatively, it has been 
suggested that autophosphorylation of ALK can occur when the receptor protein tyrosine 
phosphatase Z1 (PTPRZ1) is inactivated. 270 
Within the activation loop (A-loop) of the kinase domain (see Chapter 2.3.2.), ALK contains 
a triple tyrosine (Y1278xxxYY1283; Y = tyrosine; x = variable amino acid) motif like the insulin 
receptor kinase (IRK) subfamily. 271 Phosphorylation of the first tyrosine residue (Tyr1278) of 
this YxxxYY motif is predominant in the autoactivation of the ALK kinase domain. The amino 
acid triplet xxx, which follows immediately Tyr1278, is “RAS” in ALK (Y1278RASYY1283) and 
appears to determine in part the phosphorylation of Tyr1278 in the A-loop. This respectively 
amino acid triplet of IRK is “RTK”. 269, 271 
Binding of a ligand to the extracellular domain of RTKs induces activation of the kinase on 
the cytoplasmic side leading to intracellular signaling and, subsequently, the activated RTKs 
phosphorylate themselves and cytoplasmic substrates. 255 The endogenous ligand(s) for hALK is 
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a subject of debate. 31, 240 The mammalian ALK is not able to respond to the dALK ligand Jelly 
belly (the JEB ligand), 272 however, PTN 237 and MK 238 are suggested to be possible binders of 
hALK. Recently, ALK was reported to be activated by endogenous zinc. 273 
 
 
Regulation 
 
As earlier mentioned, ALK expression is normally restricted to only specific regions in the body 
and is normally down-regulated in the adult, resulting in very low levels of expression. 30, 245, 262 
hALK exists as a full length 220 kDa protein and a shorter 140 kDa protein, which is only found 
in the brain and in some transfected cells. 30 The shorter protein is thought to result from a 
cleavage of the extracellular domain of hALK. 239 No function of this shorter protein has been 
reported and therefore, it may be generated as part of down-regulation or degradation processes 
within the cell. 240 The cleavage of the full length protein was recently reported to be prevented 
by an as yet unidentified factor secreted by Schwann cells. 274 
The Hsp chaperones are proteins that have a critical role in the folding and maturation of 
several PKs and interact with the kinase domain region of tyrosine kinases to stabilize these 
proteins. 275-277 Among Hsps, the Hsp90 chaperone was shown to interact with NMP-ALK and 
destabilization of this Hsp90/NPM-ALK complex induced Hsp70/NPM-ALK complex formation. 
278 Since the Hsp70 is known to be involved in protein degradation, 279 the Hsps show an 
important role in regulating NPM-ALK stability and function. 
 
2.3.2 The kinase domain of anaplastic lymphoma kinase 
 
The key function of the kinase domain of PKs is to catalyze the reaction between ATP and 
generally a hydroxy group of a serine, threonine or tyrosine (see Chapter 2.1; Figure 1). Until 
recently, only a homology model of the kinase domain of ALK could be found in literature. 280 
However, crystal structures of the kinase domain of ALK complexed with various inhibitors (e.g. 
PHA-E429 (72), NVP-TAE684 (73), and staurosporine (74)) were recently published (see Figure 
30 for the crystal structure of NVP-TAE684 (73) complexed with ALK). 281, 282 The ALK 
structures reported there displayed features that are characteristic of both an inactive and active 
PK (vide infra). It is generally accepted that a high level of similarity exists for the active PK 
structures, while there are significant differences for the inactive structures. 283, 284 
The intracellular catalytic domain consists of an N- and C-terminal lobe with an ATP-binding 
site situated in a deep cleft between the domains, which is highly conserved among the PKs 
(Figure 30A and B). 285 Also the 254-amino acid catalytic domain of ALK contains the 
conserved motifs found in PKs and possesses paired tyrosine residues (ALK amino acids 1282 
and 1283) characteristic of the major autophosphorylation site of the IR subfamily. 262 The key 
regions of the ATP-binding site include the hydrophobic purine-binding cavity, the hinge 
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segment, the gatekeeper residue, the VAIK-motif, the phosphate binding (P)-loop, the activating 
(A)-loop, the catalytic loop and the regulatory αC-helix (Figure 30C). 
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Figure 30 The crystal structure of ALK complexed with NVP-TAE684 (73) (2.5 Å resolution, PDB-
code: 2XB7). 281 A) The N-terminal lobe is colored green, the C-terminal lobe is violet 
and the hinge segment is red. NVP-TAE648 (73) is removed. B) NVP-TAE648 (73, ball 
and sticks, colored by atom type) bound to the active site of the kinase domain. The hinge 
segment was deleted for the sake of clarity. The binding pocket is colored as follows: 
oxygen atoms (red), nitrogen atoms (blue), carbon atoms (green), hydrophobic groups 
(grey) and rest of the protein as in A). 
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Figure 30 C) The crystal structure of ALK complexed with NVP-TAE684 (73) (2.5 Å resolution, 
PDB-code: 2XB7). 281 Interactions between some of the pivotal amino acids and NVP-
TAE648 (73) in the ATP-binding site. The residues and NVP-TAE648 (73) are presented 
in ball and stick representations and colored by atom type. The hydrogen bonds are 
represented as green spheres. The N-terminal lobe is colored green; the C-terminal lobe 
violet; the hinge segment red; the P-loop orange; the VAIK-motif light blue; the C-helix 
blue; the DFG-motif grey; the A-loop yellow and the HRD-motif dark green. A part of 
the A-loop (residues 1275-1288) of the ALK crystal structure 3LCT 282 has been added to 
2XB7. The figures were created using ICM-Browser (version 3.7-2a, MolSoft L.L.C.). 
The hinge segment 
 
As for other PKs, the hinge segment of the kinase domain of ALK connects the N- and C-
terminal kinase domains (shown as red in Figure 30A and C). The main function of the hinge 
segment is to orientate the adenine group of ATP in the active site and that is why the segment is 
highly conserved among PKs. Furthermore, the acidic hinge residue found in the kinase domain 
of ALK, which usually interacts with the ribose group of ATP, is aspartate (Asp1203). 281 
 
The gatekeeper 
 
Immediately N-terminal to the hinge segment is the gatekeeper residue (Figure 30C). This 
residue controls the size of the ATP-binding site and is usually a bulky amino acid, thus never a 
glycine or an alanine. 286 The gatekeeper residue is an important factor in designing kinase 
inhibitors targeting the active site, since it determines, partly at least, the binding and specificity 
of the inhibitor. 280 In ALK, the gatekeeper residue is a leucine (Leu1196). 281 In many cases, 
drug resistant tumors are due to a mutation of the gatekeeper residue. 35, 280, 287 
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The VAIK-motif 
 
The VAIK-motif contains a highly conserved lysine (Lys1150) which interacts with the - and -
phosphates of ATP thus anchoring and orientating it (shown as light blue in Figure 30C, see also 
Figure 4 in Chapter 2.1; Lys72 of PKA corresponds to Lys1150 of ALK). 45 In ALK, the VAIK-
motif has a second Val residue (Val1149; Val1147-Ala1148-Val1149-Lys1150; “VAVK” in ALK) 
instead of the Ile residue usually found in PKs. 281 
 
The P-loop 
 
The P-loop is a glycine-rich loop and forms the ‘ceiling’ of the active site (shown as orange in 
Figure 30C).  The glycine residues allow the loop to be highly flexible in the absence of ATP 
and for that reason, they also help small inhibitors to enter the active site. 284 When ATP is 
present, the P-loop forms very close interactions with the phosphates of ATP, thus coordinating 
the phosphates in the active site. In addition, at the tip of the P-loop, the conserved phenylalanine 
(Phe1127 in ALK) functions as a hydrophobic cap of the active site. 
 
The A-loop 
 
Another loop found in PKs is the A-loop, where the Y1278xxxYY1283 motif can be found. The A-
loop translocates as a function of kinase phosphorylation (shown as yellow in Figure 30C). A 
large number of kinases are activated by phosphorylation of the A-loop which is typically 
disordered in its inactive state and assumes a stable structure suitable for substrate binding in its 
phosphorylated active state. 285, 288 Hence, in the inactive, unphosphorylated state of the kinase, 
the A-loop is situated in front of the ATP-binding pocket and blocks the entry of ATP. However, 
when the three tyrosines (Tyr1278, Tyr1282 and Tyr1283) are phosphorylated, a conformational 
change moves the A-loop away from the active site and allows ATP to move freely into the 
binding pocket. Subsequently, the highly conserved Asp1270-Phe1271-Gly1272 (DFG)-motif (shown 
as grey in Figure 30C), situated at the N-terminal side of the A-loop, also undergoes a 
rearrangement and the Asp1270 residue will point towards the catalytic site. This conformation 
is also called the active DFG-Asp-in conformation, whereas the inactive conformation has the 
Asp1270 pointing out from the catalytic site and is called the inactive DFG-Asp-out 
conformation. In the active DFG-Asp-in conformation, the Asp1270 forms polar interactions 
with the three phosphate groups of ATP, directly or via Mg2+ ions (see Figure 4 in Chapter 2.1; 
Asp184 of PKA corresponds to Asp1270 of ALK). 289 In addition, the Phe1271 forms 
hydrophobic interactions with the C helix (shown as blue in Figure 30C, vide infra) and the 
His1247-Arg1248-Asp1249 (HRD)-motif (shown as dark green in Figure 30C, vide infra). In 
contrast, the Gly1272 of the DFG-motif has an unknown function. The overall conformational 
change from DFG-Asp-out to DFG-Asp-in exposes a large additional cavity adjacent to the 
ATP-binding site, which has been exploited by suitably designed inhibitors. 290 
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The HRD-motif of the catalytic loop 
 
The function of the highly conserved catalytic HRD-motif (shown as dark green in Figure 30C) 
is to orientate the phosphate acceptor hydroxy group of the peptide substrate and to support the 
conformation of the A-loop/DFG-motif. 289 More specific, the His1247 binds to the Asp1270 and 
Phe1271 of the DFG-motif, the Arg1248 functions as a link between the catalytic HRD-motif, 
the phosphorylation site and the magnesium-binding-loop (consisting of the DFG-motif, 
Met1273, and Ala1274), and the Asp1249 functions as the orientating residue for the hydroxy 
group of the substrate peptide. In addition, Asp1249 has been suggested to act as a base in the 
catalytic event. 43 
 
The regulatory C-helix 
 
The C-helix (shown as blue in Figure 30C) can be found in the N-terminal lobe of the kinase 
domain. The main function of the C-helix is to stabilize the inactive and active conformations 
of the kinase domain by forming interactions with the VAIK- (VAVK in ALK) and DFG-motifs. 
284 In the crystal structure of ALK complexed with NVP-TAE684 (73), 285 Glu1167 of the C-
helix forms a conserved hydrogen bond with the conserved Lys1150 found in the VAIK-motif, a 
feature that is generally representative of an active kinase. 281 However, the kinase is inactive on 
the basis of its degree of lobe closure and the incorrect positioning of the C-helix. Thus, the 
authors suggested a drastically different autoinhibition mechanism of ALK that uses 
intramolecular interactions between the N-terminal -sheet and the DFG-helix to lock the 
structure in an inactive conformation (Figure 30C). 281 
 
2.3.3 Synthetic compounds as anaplastic lymphoma kinase inhibitors 
 
In general, ATP-competitive kinase inhibitors can be divided into two types, depending on 
whether they take advantage of the hydrophobic pocket that results from the conformational 
change of the DFG-motif in kinase activation. 281, 291 Type I inhibitors are the more common and 
recognize the active DFG-in conformation but achieve specificity only by utilizing structural 
divergence in the highly conserved ATP-binding pocket. 290 An example of a type I inhibitor is 
the ATP-competitive inhibitor crizotinib (PF-02341066, 76, Figure 31). 292 In contrast, type II 
inhibitors (e.g. imatinib (Gleevec, 77), 293 doramapimod (BIRB-796, 78), 294 and sorafenib 
(Nexavar, 79) 295), recognize the inactive DFG-out conformation 36, 37 resulting from the 
reorganization of the N-terminal portion of the A-loop that exposes a large additional 
hydrophobic cavity. 281, 290, 296 This cavity is located outside the ATP-binding pocket where less 
conserved PK residues can be found. Therefore, because the type II inhibitors do not only target 
the ATP-binding site, they are thought to show increased specificity. 293, 297 In addition, because 
the DFG-out conformation of PKs is generally less conserved than the DFG-in conformation, 298 
binding to the inactive DFG-out conformation would further increase specificity among 
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kinases. 35, 299 Type II inhibitors have also been shown to be superior in drug resistant mutants of 
PKs where even second generation kinase inhibitors have failed to show activity. 300 It is worth 
mentioning the irreversible type II inhibitors, a subtype of type II inhibitors. 287 For example, 
neratinib (HKI-272, 80) inhibits the kinase by forming a covalent bond with the kinase at the 
catalytic site, preventing ATP to bind. 301 
 
 
Figure 31 Type I (76), II (77-79), III (81) and IV (82) kinase inhibitors as well as an irreversible type II 
kinase inhibitor (80). 
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In addition to type I and II inhibitors, type III inhibitors are those, which completely bind outside 
but adjacent the ATP-binding pocket and therefore show inhibition via a non-ATP competitive 
mechanism. 36 As an example of a type III inhibitor is the pyrazolourea 81. Type IV inhibitors 
are those, which bind the kinase domain but not adjacent the ATP-binding pocket or the hinge 
region and therefore inhibit via an allosterically non-ATP competitive mechanism. 36, 302 The 
small molecule GNF-2 (82) is an example of a type IV inhibitor. 302 
There is no totally selective inhibitor of ALK available in the clinic at the moment. Recently, 
however, a growing interest in ALK has led to an increased number of publications of new drug 
candidates. Some of the most interesting compounds are presented next. 
 
Crizotinib (PF-02341066) 
 
In a screen of a panel of more than 120 PKs, Pfizer´s crizotinib (PF-02341066, 76) was found to 
inhibit NPM-ALK-catalyzed phosphorylation in human Karpas 299 ALCL cell line with an IC50 
value of 24 nM 292 and an IC50 value of 74 nM for BaF3 cell lines expressing the fusion product 
EML4-ALK. 34 On the other hand, crizotinib (76) also inhibited the RTK c-Met in human tumor 
cell lines with an IC50 value of 11 nM (Ki = 4 nM) but with the exception of these two kinases, it 
was found to be selective among the panel of the kinases tested. In a study of the sensitivity of 
500 solid tumor-derived human cell lines to 14 selective kinase inhibitors, crizotinib (76) was 
found to be selective for oncogenic ALK and c-Met containing tumors. 303 Crizotinib (76) is 
currently in clinical trials (phase I-III) for the treatment of lung cancer. 33 
 
2,4-Diaminopyrimidine-based inhibitors 
 
NVP-TAE684 (73), an inhibitor from Novartis, was identified in a cellular screen of a kinase-
directed small-molecule library to search for compounds that were selectively cytotoxic to BaF3 
NPM-ALK, but not to nontransformed parental BaF3 cells. 299 NVP-TAE684 (73) inhibited the 
proliferation of BaF3 NPM-ALK cells with an IC50 value of 3 nM (IC50 value of > 1 μM for 
parental BaF3 cells). NVP-TAE684 (73) inhibited the human Karpas 299 ALCL cell line but 
with an IC50 value of 3 nM, improved on crizotinib (76). Furthermore, among a panel of 35 BaF3 
cells transformed with various tyrosine kinases constitutively activated by fusion to the TEL 
oncogene, NVP-TAE684 (73) showed from 100 to 1000 times higher IC50 values for non-ALK 
kinases. 299 It was speculated that the specificity was a result of the bulkier hinge region residue 
at the 1198 position of the non-ALK kinases (e.g. Phe or Tyr compared to Lys found in ALK). In 
addition, NVP-TAE684 (73) was found to be superior over crizotinib (76) in the SU-DHL-1 and 
Karpas 299 lymphoma cell lines in a study where over 600 cancer cell lines were screened for 
sensitivity to an ALK selective inhibitor. 304 In another study of the sensitivity of 500 solid 
tumor-derived human cell lines to 14 selective kinase inhibitors, NVP-TAE684 (73) was found 
to be selective for oncogenic ALK containing tumors. 303 
Novartis has also patented other 2,4-diaminopyrimidines with structures similar to NVP-
TAE684 (73), including compounds 83 and 84. 305 The IC50 values of these compounds vary 
between 0.01 and 1 M, however, no further preclinical information has been published. 
Compound 85, 306 with a bromine instead of a chlorine in the 2,4-diaminopyrimidine ring, 
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inhibited EML4-ALK with an IC50 of 1 nM 307 and showed impressive results in the EML4–
ALK transgenic mouse model. 308 Oral daily doses of 10 mg/kg resulted in tumor disappearance 
in the treated animals compared to large tumor masses in the lungs of control animals. 
Cephalon has also published 2,4-diaminopyrimidines targeted to ALK. 309 Compound 86 is 
orally bioavailable and completely inhibits NPM–ALK tyrosine phosphorylation in ALCL 
tumors subcutaneously implanted in severe combined immunodeficiency (SCID) mice at an oral 
dose of 55 mg/kg. Inhibitor 86 was also effective against EML4–ALK tyrosine phosphorylation 
and induced cytotoxicity in EML4-ALK-positive NSCLC cell lines as well as in the NB-1 
neuroblastoma cell line bearing ALK amplification. 29 
Pfizer’s contribution to this class of ALK inhibitors is GSK1838705A (87), which has a [2,3-
d] fused pyrrolyl in the 2,4-diaminopyrimidine core instead of the chlorine or bromine found in 
compounds 83-86. 310 GSK1838705A (87) shows good pharmacokinetic properties, an excellent 
oral bioavailability (98%), 311 and an excellent IC50 value of ALK (0.5 nM). 310 However, it also 
inhibits the insulin-like growth factor-1 receptor (IGF-1R) and IRK with low nanomolar activity 
(IC50 values of 1.6 and 2 nM, respectively). GSK1838705A (87) showed weak or no inhibition in 
a panel of 43 other serine/threonine and tyrosine kinases (IC50 values of > 1 M). In addition, 
when GSK1838705A (87) was tested at a concentration of 0.3 M in a panel of 224 PKs it 
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inhibited only seven additional kinases > 50%. 310 GSK1838705A (87) was also shown to inhibit 
the proliferation of different tumor cell lines, such as the ALCL tumors L-82, SU-DHL-1 and 
Karpas 299 (IC50 values of 24, 31 and 52 nM, respectively) with a dose-dependent down-
modulation of NPM–ALK. 310 Furthermore, GSK1838705A (87) inhibited phosphorylation of 
EML4–ALK in the NSCLC cell line NCI-H2228 with an IC50 value of 31 nM and the 
proliferation of these cells (IC50 value of 191 nM). 310 Treatment of SCID mice bearing Karpas 
299 tumors with GSK1838705A (87) resulted in complete tumor regression at a well-tolerated 
dose of 60 mg/kg once daily. 310 
 
Pyrrolocarbazoles 
 
The staurosporine (74) analogs CEP-14083 (88) 312 and CEP-14513 (89) 312 were found to inhibit 
ALK with IC50 values of 2 and 3 nM, respectively. 313 In addition, both CEP-14083 (88) and 
CEP-14513 (89) showed cellular IC50 values of 10-30 nM for NPM-ALK phosphorylation in 
ALCL cells. Furthermore, CEP-14083 (88) was shown to induce growth arrest and cell death in 
neuroblastoma cells overexpressing WT or mutated ALK when tested at 60 nM, indicating a 
potential therapeutic strategy for neuroblastoma patients. 314 Interestingly, the pyrrolocarbazole 
CEP-11988 (90) did not show any inhibitory activity (IC50 value > 20 μM). 312 
 
 
SKI-606 
 
Initially designed as a dual kinase inhibitor of the c-Src (sarcoma tyrosine kinase) and c-Abl 
(Abelson tyrosine kinase) kinases, 315 SKI-606 (91) was shown to inhibit the L256T mutant 
NPM-ALK (numbering of the NPM-ALK fusion gene) with an IC50 value of 150 nM. 280 
However, SKI-606 (91) did not inhibit the WT ALK, which was explained by the larger 
gatekeeper residue (threonine vs. leucine) in the kinase domain of the WT ALK. Docking 
experiments of SKI-606 (91) to homology models of ALK in an intermediate or active 
conformation of both the mutant and the WT, confirmed the experimental results. In contrast, 
imatinib (77), inhibited neither the L256T mutant nor the WT ALK. 
53 
 
N
MeO
ON
NMe
HN
CN
OMe
Cl
Cl
SKI-606 (91) PD173955 (92)
N
NN N
H
SMe
Me
OCl
Cl
 
 
PD173955 
 
The Src 316 and breakpoint cluster region (Bcr)-Abl 317 kinase inhibitor PD173955 (92) has also 
been shown to inhibit the L256T mutant NPM-ALK but with an IC50 of only 2.5 μM. 280 As for 
SKI-606 (91), PD173955 (92) did not inhibit the WT ALK. 
 
Quinazoline-based inhibitors 
 
The quinazoline-based inhibitors WHI-P131 (93) and WHI-P154 (94) inhibit NPM-ALK 
enzymatic activity with modest IC50 values in in vitro kinase and cell proliferation assays (10 and 
5 M, respectively). 318 These inhibitors are structurally closely related to the epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitors erlotinib (Tarveca, 95) 319 and gefinitib (Iressa, 
96), 320 which are used as drugs against NSCLC, pancreatic cancer and several other types of 
cancers. Erlotinib (95) has also been studied in a clinical trial (phase II) for patients showing the 
EML4-ALK translocation. 33 However, EML4-ALK-positive cells have been shown to be 
resistant to erlotinib (95) and gefinitib (96). 321 
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Pyridone-based compounds 
 
Co-operation between ChemBridge Research Laboratories and St Jude Children’s Research 
Hospital resulted in a discovery of pyridone-based inhibitors of ALK. 322, 323 After lead 
optimization rounds, the best inhibitor (97) showed an IC50 value of 0.4 M for ALK. Pyridone 
97 showed selective inhibition of ALK compared to the tyrosine kinases IRK, IGF-1R, fms-like 
tyrosine kinase receptor-3 (Flt3), Src and Abl (10-fold, 18-fold, > 10-fold, > 50-fold and > 50-
fold, respectively), however, even though compound 97 showed activity in cell-based 
antiproliferative assays (NA/BaF3, BaF3, Karpas 299, K562 and Jurkat), it did not show 
selectivity among them. 
Another ChemBridge–St Jude compound that displays ALK-inhibitory activity is the 
pyridone 98, showing an IC50 value of “less” than 0.5 M. 324 However, pyridone 98 is non-
selective among the IR superfamily (e.g. IR and IGF-1R) and also in cell-based antiproliferative 
 assays. 266 
Recently, the same co-operation between ChemBridge–St Jude has yielded a third generation 
ATP competitive and ALK inhibiting pyridone-based compound (CRL151104A), however, no 
structural information has been published. 266, 324 CRL151104A shows an ALK IC50 value of 10 
nM when measured at 100 M ATP and showed little or no inhibition of ten structurally diverse 
serine/threonine kinases (when tested at a 50 nM concentration). CRL151104A also showed a 
dose-dependent growth inhibition of the Kelly (F1174L), SH-SY5Y (F1174L) and CHLA-90 
(F1245V) neuroblastoma cell lines, with IC50 values of 610, 500 and 370 nM, respectively. In 
addition, cellular cytotoxicity assays of NPM–ALK-dependent human ALCL cell lines (Karpas 
299, SU-DHL-1, JB6, SUP-M2, UConnL2) demonstrated potent inhibition (IC50 values < 100 
nM); by contrast, the lowest IC50 value observed for 12 non-ALK-dependent cell lines was 
approximately 2.5 M, indicating a minimum 25-fold differential cytotoxicity. 266 Furthermore, 
neuroblastomas with aberrant forms of ALK harboring activating point mutations, such as 
R1275Q, are sensitive to this ALK inhibitor, making CRL151104A an interesting future 
inhibitor. 
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Pyrazolo[3,4-c]isoquinoline-based inhibitors 
 
One structurally new class of ALK inhibitors is the pyrazolo[3,4-c]isoquinolines (compound 99 
as a representative example). 325 To date, the only available information for this class of ALK 
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inhibitors can be found in the patent, where the structures for over 240 pyrazolo[3,4-
c]isoquinolines are presented. The IC50 values of the compounds are reported to be “less or equal 
to 99 nM” but also “greater than 2000 nM”. 
 
 
Tetrahydropyrido[2,3-b]pyrazines 
 
Another new class of ALK inhibitors is the tetrahydropyrido[2,3-b]pyrazines. 326 Cephalon 
scientists made a rigid derivative of crizotinib (76) by fusing the -amino pyridinyl ring found in 
crizotinib (76). Inhibitor 100 showed an IC50 value of 10 nM for ALK and also inhibited ALK 
phosphorylation in Karpas 299 cells with an IC50 value of 200 nM. Importantly, compound 100 
showed selectivity over IR in particular (IC50 value > 3000 nM of IR), and over other kinases in 
general. Furthermore, when compound 100 was screened at 1 M across a panel of 400 kinases, 
including representative kinases from all the known kinase families, it inhibited only 2.2% of the 
kinases by more than 90%. Another tetrahydropyrido[2,3-b]pyrazine inhibitor by Cephalon is 
compound 101, which displayed an even better IC50 value for ALK (3 nM). 327 
 
 
 
-Carbolines 
 
The -carbolines (102-105) are another new group of ALK inhibitors. 328 The only information 
available for these compounds is the patent where the compounds are reported as NPM-ALK, 
RET and Bcr-Abl inhibitors, with the IC50 values of ALK starting from 0.4 μM (compound 102). 
The same researchers have also reported the synthesis of these kinds of compounds. 329, 330 
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IPI-504 
 
IPI-504 (retaspimycin hydrochloride, 106), 331 a novel intravenous (IV)-administered Hsp90 
chaperone inhibitor, was recently shown in a phase II study to demonstrate clinical activity in 
NSCLC patients, particularly among those with oncogenic ALK gene rearrangements. 332 IPI-
504 (106) is a semisynthetic inhibitor, prepared in two steps from the antibiotic geldanamycin 
(108, vide infra). 331, 333 In 2011, IPI-504 (106) will be further investigated in a phase II study by 
Infinity Pharmaceuticals as an inhibitor in NSCLC patients with ALK translocations. 33 
 
 
AP26113 
 
An ALK inhibitor with no structural information available is AP26113. 34, 334, 335 Discovered by 
scientists of Ariad Pharmaceuticals, AP26113 is a very potent (IC50 = 0.58 nM), orally available 
ALK inhibitor with a broad therapeutic index including the potential for once-daily oral dosing. 
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In addition, AP26113 is claimed to show approximately 100-fold selectivity for ALK-positive 
cell lines compared to ALK-negative cell lines and maintenance of significant selectivity over 
the highly similar IGF-1R and IRK (IC50 of 38 and 262 nM, respectively). Compared to 
crizotinib (76), AP26113 has shown in vitro to have 10-fold greater potency, a 10-fold broader 
therapeutic index, and an in vivo efficacy equivalent to crizotinib (76) at 4- to 10-fold lower 
levels of exposure. Ariad Pharmaceuticals expects to advance AP26113 into clinical 
development in 2011. 
 
 
Summary of the synthetic compounds targeting ALK 
 
Several rationally designed inhibitors of ALK and its fusion products can be found in the 
literature. One of the recent drug candidates is crizotinib (76), 292 which is in clinical trials for the 
treatment of lung cancer. 33 Since the catalytic domain is highly conserved among PKs, target 
specificity of the compounds is required. In particular, selectivity over the IR superfamily is 
crucial, since dysregulation of normal metabolic pathways should be avoided. 
Among the most selective inhibitors targeting ALK or its fusion products are crizotinib 
(76), 33 NVP-TAE684 (73), 299 the tetrahydropyrido[2,3-b]pyrazines (e.g. 100) 326 and AP26113, 
however, with no structural data available. 34, 334, 335 The Leu1198 of ALK, compared to 
generally bulkier amino acids in other kinases, was suggested to be the structural basis for the 
selectivity among the 2,4-diaminopyrimidine-based inhibitors having an ortho methoxy group 
attached to the 2-aniline substituent. 299 
 
2.3.4 Natural compounds as anaplastic lymphoma kinase inhibitors 
 
 
Ansamycins 
 
To date, only a few inhibitors of ALK activity from natural sources have been reported. The 
fusion product NPM-ALK shows sensitivity in ALCLs to the antibiotics herbimycin A (107), 336 
geldanamycin (108) 337 and 17-allylamino-17-demethoxygeldanamycin (17-AAG, 109). 278 
These ansamycin antibiotics 107-109 display their activity in the ALCLs via the inhibition of the 
Hsp90/NPM-ALK complex formation, enhancing the proteasome-enhanced degradation of ALK. 
278 Because Hsp90 chaperones have many client proteins, these Hsp90 inhibitors are not specific 
for ALK inhibition. However, the ansamycin antibiotics 107-109 have been in clinical trials for 
the treatment of various cancers. 33 
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Staurosporine and 7-hydroxystaurosporine 
 
Staurosporine (74) is an antibiotic isolated from bacterium Streptomyces staurosporeus. 338 
Staurosporine (74) is an ATP-competitive inhibitor that unselectively inhibits many kinases. 339 
Not surprisingly, staurosporine (74) was shown also to inhibit ALK with an IC50 value of 
approximately 130 nM in the presence of 30 M ATP. 340 The IC50 value for staurosporine (74) 
increased to approximately 700 nM when the ATP concentration was increased 10-fold, 
reflecting well an ATP-competitive inhibition. 
Anti-tumor activity in a patient with an ALK-positive ALCL was reported in a phase I 
clinical trial in response to 7-hydroxystaurosporine (UCN-01, 75). 341 However, 7-
hydroxystaurosporine (75) showed a relatively high IC50 value of 5 M in the presence of 30 M 
ATP and no inhibition when it was tested in the presence of 300 M ATP. 340 
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3 Aims of the study 
During the past decades, it has become clear that malfunctioning PKs cause cancer. One way of 
combating this problem has been to develop ligands that target these PKs and consequently 
prevent this harmful disease. However, lack of suitable ligands, gene mutations, resistant cancer 
lines and the constant discovery of new target kinases are the main driving forces that keeps 
cancer research ongoing. 
The primary objective in this study was to design and synthesize novel inhibitors and 
activators targeting either the regulatory domain of PKC or the kinase domain of ALK. Another 
primary objective was to synthesize bistramide A analogs. Potent lead compounds, which had 
been identified by computational methods, were used as templates in the design. Therefore, one 
of the aims of this study was to design and synthesize compound libraries with hit compound-
based derivatives for the investigation of SARs of the PK ligands. 
 
The more specific aims of the research were 
 
• to synthesize a new class of compounds that induce apoptosis in leukemia cells (I); 
 
• to design and synthesize a compound library based on the hit compound targeted to the 
C1 domain of PKC and to study the SAR of these compounds (II); 
 
• to design and synthesize bistramide A and some of its isomers for biological studies (III); 
 
• to design and synthesize inhibitors based on lead templates targeted at the kinase domain 
of ALK and to study the SAR of these compounds (IV). 
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4 Experimental 
A detailed presentation of the materials, synthetic, and analytical methods can be  found  in  the  
original  publications  I-IV  and  in  the  supporting  information  for  original publications II, III 
and IV. 
  
The supporting information for original publications II, III and IV is not included in this thesis 
book. This material is available from the author or via the Internet at http://pubs.acs.org for 
original publication II (46 pages) and at http://onlinelibrary.wiley.com/ for original publications 
III (78 pages) and IV (16 pages). 
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5 Results and discussion 
The design, synthesis and SAR of PK ligands are described in the following chapters; dialkyl (5-
hydroxymethyl)isophthalates and isophthalic acid derivatives (Chapter 5.1), bistramide A and its 
derivatives (Chapter 5.2) and urea-based inhibitors (Chapter 5.3). None of the reaction 
conditions presented here was systematically optimized since more emphasis was put on 
producing derivatives than optimizing reaction yields. Primarily those reactions which cannot be 
found in the original publications I-IV are presented here. 
5.1 Synthesis of isophthalic acid derivatives and SAR of the 
compounds (I and II) 
 
Identification of dialkyl (5-hydroxymethyl)isophthalates as compounds inducing apoptosis (I) 
 
At the beginning of this research project, dipentyl (5-hydroxymethyl)isophthalate (110) among 
other hit compounds, had been discovered II using molecular modeling and the crystal structure 
of the PKC C1b domain (Figure 32A). 81 This C2-symmetric compound (110) was used as a 
template for the design of a compound library for the SAR of the compounds. 
 
 
First, the hit compound (110) was docked into the crystal structure of the C1b domain of PKC 
(Figure 32A). 81 As can be seen, compound 110 fits deeply in the binding cleft and forms similar 
hydrogen bonds to the protein as does phorbol 13-O-acetate (7) (Figure 32B, Figure 8 and 
Chapter 2.2.2.). Encouraged by these results, a number of derivatives of the hit compound (110) 
were designed. 
In order to find the optimal ester groups for activity, synthesis of derivatives of the hit 
compound (110) was required. As the structurally related diethyl (5-hydroxymethyl)isophthalate 
(111) is commercially available, it was logical that it could serve as a starting material in the 
synthesis of the analogs. I, II Using 111 as a starting material, a set of ten symmetric diesters 
(compounds 110, 112-119, and 127) could be prepared in only four reaction steps with overall 
yields of 22-46% (Figure 33). I None of the reaction conditions were systematically optimized 
since the main aim was to produce derivatives for biological activity assays. 
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Figure 32 A) The hit compound (110) docked into the crystal structure (PDB ID: 1PTR) 81 of the C1b 
domain of PKCδ. The hit compound (110) is presented in ball and stick representation and 
colored by atom type. The binding pocket is colored as follows: oxygen atoms (red), nitrogen 
atoms (blue), carbon atoms (green), hydrophobic groups (grey) and rest of the protein 
green. Hydrogen bonds are denoted with green spheres. B) Phorbol 13-O-acetate (7) in the 
crystal structure (PubID: 1PTR) of the C1b domain of PKCδ. 81 Colored as in A). The 
figures were created using ICM Molsoft software 3.7. 
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Figure 33 Synthesized dialkyl (5-hydroxymethyl)isophthalates (112-136), the starting material (111) 
and the negative control compound (137). The modified position of the hit compound (110) is 
indicated with a circle. 
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The first set of compounds (110, 112-119, and 127) was tested for proapoptotic activity in HL-60 
leukemia cells and in Swiss 3T3 fibroblasts (Figure 34). Compounds 114 and 119 were found to 
be the most promising of the studied compounds; they induced apoptosis on HL-60 leukemia 
cells (43 and 47%, respectively, of apoptotic cells at 20 μM) and their effects on fibroblasts at 
these concentrations were insignificant (< 5% at 20 μM). In addition, reduction in mitochondrial 
membrane potential (m) and increase in caspase-3 activity already during the first 2 hours 
confirmed these results. Compounds 114 and 119 showed IC50 values (for HL-60 cells) of 41 and 
23 μM, respectively. The other compounds had weaker apoptosis-inducing effects in leukemia 
cells or they were non-selective. Interestingly, the hit compound (110), structurally different 
from compound 119 by only one carbon in both ester side chains, showed only a moderate 
apoptotic activity in leukemia cells (15% at 20 μM) and little effect on fibroblasts. Importantly, 
compounds 114 and 119 were not cytotoxic or mutagenic, shown by a lactate dehydrogenase 
assay and with a miniaturized Ames test. 
 
  
Figure 34 Apoptotic activity in HL-60 leukemia cells for the tested compounds. The compounds were 
tested at concentrations of 100 μM (black bars), 60 μM (light grey bars) and 20 μM (dark 
grey bars). 
 
Structure-activity relationship of isophthalic acid derivatives (I and II) 
 
In a second round of synthesis, the diesters 120-126 and 128-136, and the negative control 
compound 137 were prepared (Figure 33). II The ester groups of the compounds were chosen to 
investigate: i) the optimal ester group for activity; ii) the optimal clogP value for activity and 
whether the clogP value could be increased and iii) the structure of the binding pocket. The 
syntheses of the analogs 120-126 and 128-136 were completed as for the previous compounds 
and with 8-78% overall yields. Subsequently, the diesters 113-114 and 118-137 were screened 
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for binding activity to PKC and PKC using a filtration method in a 96-well plate format. 342 
The diesters 113-114 and 118-133 (tested at 0.1-20 μM concentrations) replaced [3H]PDBu (25 
nM concentration) from PKC and PKC with 32-67% and 48-77%, respectively (Figure 35). 
Compounds 134-137 were not able to replace [3H]PDBu from PKC or PKC. In addition, the 
diesters replaced [3H]PDBu in a concentration-dependent manner (Figure 36, partly unpublished 
results, Talman et al.). II, 343 When comparing their ability to replace [3H]PDBu from PKC, the 
best derivatives (128-131) generally had ester groups derived from secondary alcohols with 6-7 
carbons. Furthermore, a modest selectivity between PKC and PKC could be obtained; the 
compounds seemed to replace [3H]PDBu better from PKC than PKC in most cases (Figure 
35). Compounds 114, 128, and 129 displayed Ki values of 205 and 590 nM, 661 and 915 nM, 
and 319 and 529 nM for PKC and PKC, respectively. 
 
 
Figure 35 The bars represent the percentage of the replaced [3H]PDBu from PKC (black bars) and 
PKCδ (grey bars) when 20 μM of the compounds were tested, expressed as percentage of 
control (n = 1-8). The concentration of [3H]PDBu was kept at 25 nM. 
The clogP of C1-domain binding compounds seem to affect, at least to a certain degree, the 
ability of replacing [3H]PDBu from the C1 domain because the C1 domain is thought to be in 
close proximity to the bilayer. 81, 230 Analysis of the binding activity for PKC vs. the clogP of 
the synthesized compounds revealed an optimum clogP-value of greater than 5.5 (Figure 37). 
Compounds 134-136 were designed and synthesized in an attempt to reduce the hydrophobicity 
of the compounds keeping in mind not to change the overall structure too much (compare the 
structure of these compounds to compounds 110 and 119). However, introducing an additional 
oxygen atom to the ester substituents decreased binding activity (Figure 35 and Figure 37). The 
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decreased binding affinity of these compounds with relatively more hydrophilic ester groups may 
be due to unfavorable interactions within the bilayer. 100, 344 Because activated PKC C1 domains 
translocate partly into the membrane, using hydrophilic side chains in the compounds may be 
one possibility for development of specific C1 domain-targeted ligands. 345 However, in the case 
of dialkyl 5-(hydroxymethyl)isophthalates this remains to be seen. 
In a next round of SAR study we investigated how important the hydroxymethyl group found 
in the template (110) is for binding activity. To do this, we designed a series of compounds (138-
143) having the same ester groups as in compounds 114 or 120 but the hydroxymethyl group was 
substituted with a proton, methyl, nitro or amino group (Figure 38). 
OO
OO
OO
OO
NO2 143
F
F F
F
F F
Y
Y = H (138)
Y = Me (139)
Y = NO2 (140)
Y = NH2 (141)
OMeO
OO
142H
 
Figure 38 Analogs (138-143) lacking the hydroxymethyl group of the hit compound 110 but having 
instead a proton (compounds 138 and 142), methyl (compound 139), nitro (compounds 140 
and 143), or amino (compound 141) group. The modified position of the hit compound (110) 
is indicated with a circle. 
These analogs were conveniently synthesized in only one step with 28-76% yields. II The amino 
analog 141 was prepared by catalytic hydrogenation of the nitro group in 140 with a 77% yield 
(Scheme 1, unpublished results, Boije af Gennäs et al.). 346 
 
Scheme 1a. 
 
a Conditions: (a) Pd/ C (10%), EtOH, rt, 18 h, 77%. Unpublished results. 346 
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The results from the biological assays clearly showed that the hydroxymethyl group of the hit 
compound (110) is needed for binding activity since the derivatives 138-143 were not able to 
replace [3H]PDBu from the C1 domain of PKC or PKC (Figure 39, partly unpublished results, 
Talman et al.). II, 343 
 
 
Figure 39 The bars represent the remaining [3H]PDBu bound to PKC (black bars) and PKC (grey 
bars), expressed as percentage of control (n = 1-3). The concentrations of the compounds 
were 20 μM and the concentration of [3H]PDBu was 25 nM. Partly unpublished data, 
Talman et al. II, 343 
Since amide groups are more hydrophilic than ester groups, and amides are also more stable than 
esters in the cells, 347 the substitution of one or both of the ester groups of the hit compound 
(110) with amide group(s) or reverse amide group(s) was pursued. In addition, nonsymmetric 
compounds could also increase the binding affinities to the binding site of the C1 domain. 
Compounds 114 and 119 were chosen as templates for the amides because they had previously 
shown good binding activity and the respective amides were readily synthesizable, hence 
compounds 144 and 145 were prepared (Figure 40). The reverse amide 146 was synthesized to 
investigate the effect of moving the carbonyl group, which was thought to be important for 
activity, one atom away from the aromatic ring. In addition, compounds 147-151 and 152 were 
designed to study the binding potency of nonsymmetric monoester and -amide compounds 
(Figure 40). In these compounds one pivotal ester group was kept and the other one substituted 
with an amide group. 
Unfortunately, all of these compounds bound less strongly than the diesters (Figure 41). The 
binding activity results were surprising, taking into account that the only difference in the 
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Figure 40 Compounds with one (152) or two (144 and 145) amide or reverse amide (146-151) groups. 
The modified position of the hit compound (110) is indicated with a circle. 
structure of the amides compared to the esters is the amide groups (compare e.g. 144 and 145 to 
119 and 114). Structurally, the amide groups are more rigid than the ester groups, which may 
contribute negatively/unfavorably to the overall binding activity. However, inspection of the 
crystal structure does not confirm why these amides would not bind the regulatory domain. 
Interestingly, compound 147, having the longest and most hydrophobic amide group of the 
monoamine series (compounds 147-152), showed the best ability to replace [3H]PDBu from 
  
 
Figure 41 Representation of the remaining [3H]PDBu bound to PKC (black bars) and PKC (grey 
bars), expressed as percentage of control (n = 3). The compounds were assayed at a 
concentration of 20 μM and the concentration of [3H]PDBu was 25 nM. 
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PKCα and PKC. One explanation of these binding results may again be the interactions of the 
ligands within the bilayer; a more hydrophilic amide group may result in unfavorable 
interactions. 100, 344 
 
In the next rounds of SAR studies we wanted to investigate analogs of the hit compound that 
contain only one ester group. Hence, two series of compounds were synthesized; one series 
(compounds 153-155) II where the compounds lack one of the ester groups and another series 
(compounds 156-159), where the compounds have only one ester group but instead one 
additional hydroxy or ether group inserted (Figure 42, partly unpublished results, Boije af 
Gennäs et al.). II, 346 Compounds 156-159 were synthesized in two or three steps starting from 5-
formyl-2-hydroxybenzoic acid (160, Scheme 2). The phenol 156 was prepared by 
monoalkylation of 160 by 1-hexyl bromide and KHCO3 in DMF at 80 °C for 4 h and subsequent 
NaBH4 reduction of the intermediate (161) to give the product in 56% yield (two steps, 
unpublished data). 346 Derivatives 157 and 158 were obtained after dialkylation of 160 by alkyl 
bromide, KI and K2CO3 in DMF at 110-130 °C for 17-18 h and subsequent NaBH4 reduction of 
the intermediates (162 and 163) to give the products  in 62-71% yields (two steps, unpublished 
data). 346 Analogue 159 was prepared from 161, benzyl bromide, KI, K2CO3 in DMF under 
microwaves at 130 °C for 1 hour and subsequent NaBH4 reduction of the intermediate (164) to 
give the product in 34% yield (two steps, unpublished data, Boije af Gennäs et al.). 346 
 
 
 
Figure 42 Compounds 153-159 carrying only one ester group. The modified positions of the hit 
compound (110) are indicated with circles. Partly unpublished compounds, Boije af Gennäs 
et al. II, 346 
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Scheme 2a. 
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a Conditions: (a) alkyl bromide (1.1 equiv.), KHCO3, DMF, 80 °C, 4 h, 57% (161) or alkyl 
bromide (2.0-2.5 equiv.), K2CO3, KI, DMF, 110-130 °C, 17-18 h, 86-90% (162 and 163); (b) 
benzyl bromide (2.0 equiv.), K2CO3, KI, DMF, 130 °C, 1 h, 60% (164); (c) NaBH4, MeOH (and 
THF), 0 °C, 2-4 h, 56-99%. Unpublished data, Boije af Gennäs et al. 346 
 
The compounds were screened for binding activity and as expected, the monoesters 153-155 did 
not show any activity (Figure 43). II In addition, phenol 156, with a hydroxy group ortho to the 
ester group, did not show any binding activity (unpublished results, Talman et al.). 343 Instead, 
compound 157, with an ortho 1-hexyl ether group, replaced [3H]PDBu effectively from PKC 
and less effectively from PKC (Figure 43, unpublished results, Talman et al.). 343 These results 
suggest that a polar group is unfavorable at this position, underlining the hypothesis that PKC 
C1-domain modulators create a hydrophobic surface over the binding cleft. 62 In contrast, 
compound 159 with a benzyl ether group instead of the 1-hexyl ether group present in 157, could 
not replace [3H]PDBu from PKCα and PKC. The reason for this difference in binding activities 
between these two compounds is hard to explain, one explanation may be that the benzylic ether 
group of 159 forms unfavorable interactions with the Leu254 of the C1 domain. Compound 158, 
with longer alkyl chains than 157 and 159, also showed weak binding activity. All together, these 
results demonstrate that two ester groups are not needed for binding activity to the C1 domain of 
PKCα and PKC but if the derivative only has one ester group an (ortho) ether group is required. 
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Figure 43 The bars represent remaining [3H]PDBu bound to PKC (black bars) and PKCδ (grey 
bars). The compounds were assayed at a concentration of 20 μM in the presence of 25 nM 
[3H]PDBu, and are % of control (n = 3). Partly unpublished results, Talman et al. II, 343 
To conclude, the SAR results gave the following information (Figure 44): i) at least one carbonyl 
of 110 is needed for activity, however, ii) if one of the ester groups of 110 is replaced by 
hydrogen, a hydrophobic group next to the second ester group is needed for activity, iii) the 5-
hydroxymethyl group of 110 is needed for activity, iv) the best compounds have ester groups 
consisting of secondary alkoxy groups of 6-7 carbons, v) an additional oxygen atom in the side 
chains of the ester groups is not tolerated and, vi) one or both of the ester groups cannot be 
substituted with amide or reverse amide groups. 
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Figure 44 Results from the SAR studies. 
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5.2 Synthesis of bistramide A and its derivatives, and the biological 
outcome of the compounds (III) 
 
At the beginning of this project, there was little consensus on the activation of PKC by 
bistramide A (30). While PKC was initially discovered to be activated by bistramide A (30) in 
HL-60 and MM96E cells, 170 more recently another group has identified that the main target of 
bistramide A (30) is actin. 172 Therefore, the synthesis of analogs of bistramide A (30) to study 
the biological outcome of these structural modifications was pursued. 
As bistramide A (30) possesses two amide groups, it was logical that its analogs could be 
obtained from the corresponding carboxylic acids and amines (Figure 45). Three building blocks 
were assigned; the south fragment (165), the central fragment (166) and the north fragment 
(167). These fragments were synthesized as a collaboration between three research groups; the 
south (165) and north (167) fragments were prepared in the University of Lyon (France) by two 
research groups and the central fragment (166) as part of this investigation in Helsinki. The 
couplings of the fragments were performed in the French laboratories. 
 
Figure 45 Retrosynthesis of bistramide A (30) giving the south (165), the central (166) and the north 
(167) fragments. 
Depending on the coupling strategy used in the synthesis of bistramide A (30), the protections 
and activations of the functional groups of the south (165), the central (166) and the north (167) 
fragments have to be carefully chosen. Among previously performed total syntheses of 
bistramide A (30), the most common protocol has been to couple first the north fragment (167) 
with the central fragment (168) followed by the coupling of the south fragment (171) (Figure 
46). 177-179 Hence, the secondary hydroxy and carboxyl groups of the south (171) and central 
(168) fragments have been protected with tert-butyldimethylsilyl (TBS) and triisopropylsilyl 
(TIPS) groups. 
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Figure 46  Coupling strategy of fragments in the synthesis of bistramide A (30). 177-179 
In contrast to the above-mentioned coupling strategy in the synthesis of bistramide A (30), the 
groups of Kozmin 175 and Crimmins 176 performed the coupling reaction first with the south 
(165) and the central (173) fragments followed by the condensation of the north fragment (176) 
 
 
Figure 47 Coupling strategy of Kozmin 175 and Crimmins 176 of the fragments in the synthesis of 
bistramide A (30). 
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(Figure 47). In this strategy, only the amino group of the central fragment (173) needs to be 
protected as a fluorenylmethyl carbamate (Fmoc, compound 173) and consequently, the number 
of required deprotection steps is reduced. Therefore, we decided to use this coupling strategy in 
the synthesis of bistramide A (30) as well as its analogues. 
 
 
The central fragment (173) was prepared in seven steps with an overall yield of 21% using the 
modified Kozmin synthesis route (Scheme 3). 175 Instead of the Brown crotylboration 348 of the 
amino aldehyde (182) used in the Kozmin route, we performed an asymmetric crotyltitanation 349 
of the aldehyde (182). 350 In this reaction, the highly face-selective crotyltitanium complex (181), 
351 which was synthesized from (4R,5R)-2,2-dimethyl-,,,-tetraphenyldioxolane-4,5-
dimethanol (TADDOL, 177), cyclopentadienyltitanium(IV) trichloride (178) and 2-
butenylmagnesium chloride (180), allowed the introduction of the desired stereochemistry of the 
amino alcohol (183). The use of a crotyltitanation instead of a crotylboration allowed us to avoid 
the usage of the highly volatile trans-2-butene used in the Kozmin route. 175 While having the 
right stereochemistry in hand, the amino alcohol (183) was protected as the 1,3-oxazolidine 
(184) and subsequent ruthenium chloride - periodate catalyzed oxidative cleavage of the double 
bond under Sharpless conditions 352 gave the carboxylic acid (185). The optical purity of the 
carboxylic acid (185) was confirmed by diazomethane derivatization and chiral GC-MS. Acidic 
deprotection of the 1,3-oxazolidine (185) to the amino acid (186) and subsequent introduction of 
a Fmoc group gave the N-protected amino acid 173. Optical rotations measured of the products 
were in good agreement with those previously reported. 175 
 
 
Inspection of the crystal structure of actin complexed with bistramide A (30) reveals hydrogen 
bonds between the ligand and the protein (Figure 48). 180 Two hydrogen bonds between the 
protein and the central fragment (166) region of bistramide A (30) can be obtained; one between 
the phenol group of Tyr133 and the C17 carbonyl group and another between the backbone 
amide proton of Ile136 and the C15 hydroxy group. In addition, the two other hydrogen bonds 
which can be obtained in the binding complex interact with the amide groups of bistramide A 
(30). The first hydrogen bond is between the phenol group of Tyr143 and the amide proton of the 
south fragment (165) region and the second is between the backbone amide proton of Ala170 
and the C12 carbonyl of the north fragment (167) region. Three additional hydrogen bonds 
between bistramide A (30) and actin residues can be obtained via bridging water molecules 
(Figure 48 and Figure 49). In addition, the C16 methyl group of the central fragment (166) 
appears to point towards a hydrophobic cave in the binding pocket. All in all, the central 
fragment (166) region appears to play an important role in the overall binding affinity of 
bistramide A (30) to the protein. 
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Scheme 3a. 
 
a Conditions: (a) Et3N, Et2O, rt, 24 h; (b) 2-Butenylmagnesium chloride (180) (2 M in THF), 
Et2O, 0 °C, 80 min; (c) i) tert-Butyl N-(2-oxoethyl)carbamate (182), THF, -78 °C, 20 h; ii) NH4F 
(40%, aq.), -78 °C  rt, 24 h, 57% (three steps); (d) p-Toluenesulfonic acid monohydrate, 2,2-
dimethoxypropane, acetone, rt, 10 min, 70%; (e) NaIO4, RuCl3, CCl4:MeCN:H2O (2:2:3), rt, 17 h, 
66%; (f) HCl (3 M, aq.), EtOAc, rt, 3 h, 100%; (g) N-(9-Fluorenylmethoxycarbonyloxy) 
succinimide, Na2CO3, H2O:1,4-dioxane (1:1), rt, 2 h, 80%. 
 
 
A closer look at the crystal structure of actin complexed with bistramide A (30) showed that the 
C39 hydroxy of bistramide A forms a hydrogen bond with the carbonyl of Tyr143 via a bridging 
water molecule (Figure 49A). By inverting the stereochemistry of the double bond, the same 
hydroxy may be placed in close proximity to the Tyr143 carbonyl, which would allow a direct 
hydrogen bond formation (Figure 49B). Therefore, bistramide A (30) as well as the 36(Z)-39(R) 
(187) and 36(Z)-39(S) (188) isomers of bistramide A (30) were prepared in order to test this 
hypothesis. III 
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Figure 48 The crystal structure of actin complexed with bistramide A (30) (1.35 Å resolution, PDB ID: 
2FXU). 180 A) The binding pocket is presented as a surface and is colored as follows: oxygen 
atoms (red), nitrogen atoms (blue), carbon atoms (green), hydrophobic groups (grey) and 
rest of the surface is colored green. Bistramide A (30) and water molecules are presented in 
ball and stick representation and colored by atom type. Hydrogen bonds are denoted with 
green spheres. B) Residues Tyr133, Ile136, Tyr143 and Ala170 that contribute to the binding 
of bistramide A is shown in ball and stick representation and are colored as in A). Secondary 
structures of the protein are colored with different colors and hydrogen bonds are denoted 
with green spheres. The figures were created using ICM Molsoft software 3.7. 
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Figure 49 A) The crystal structure of actin complexed with bistramide A (30) (PDB ID: 2FXU). 180 The 
C39 hydroxy of bistramide A (30) is forming a hydrogen bond with Tyr143 via a bridging 
water molecule. Bistramide A (30) and residues Tyr143, Ala144, Ser145 and Gly146 are 
presented in ball and stick representation and colored by atom type. Secondary structures of 
the protein are colored orange and green, and hydrogen bonds are denoted with green 
spheres. B) The 36(Z)-39(S) isomer 188 of bistramide A (30) obtained by substitution in the 
X-ray structure of the bistramide A-actin complex, showing the expected hydrogen bond of 
the C39 hydroxy to the carbonyl of Tyr143. Colored as in A). The figures were created using 
ICM Molsoft software 3.7. 
First, to determine the effects of the natural product (30) and the 36(Z)-isomers (187) and (188) 
on cell viability, they were tested in HL-60 cells using the MTS assay. The MTS assay is a 
colorimetric assay used in detecting living, but not dead cells, and can therefore be used to 
measure cytotoxicity, proliferation or activation of cells. 353 This overall antiproliferative assay 
showed slightly weaker activities for the Z isomers 187 and 188 compared to bistramide A (30); 
the concentrations required to inhibit growth by 50% (IG50) were 1.6, 7.8 and 3.7 μM for 
bistramide A (30), the 36(Z)-39(R) and the 36(Z)-39(S) isomers 187 and 188, respectively. As 
the observed growth inhibition can be attributed to a combination of inhibition of cell cycling 
(antimitotic effect), proapoptic effect, and induction of differentiation, a more detailed cell cycle 
analysis by flow cytometry was performed on the HL-60 cells. Indeed, while the isomers showed 
similar overall antiproliferative activities, flow cytometry analyses showed significant 
differences regarding the origin of this activity. Each compound showed a distinct distribution of 
antimitotic effect presumably via actin binding, proapoptotic effect most likely via PKC, and 
pro-differentiation effect as evidenced by CD11b expression. 
The results of bistramide A (30) were consistent with inhibition of cytokinesis via actin as 
previously reported, 172 however, at high concentrations (100 μM) the results were consistent 
with the induction of apoptosis. The results for the 36(Z)-39(R) isomer 187 show a similar strong 
accumulation in 4n polyploid cells, with no corresponding accumulation in sub-G0 phase of the 
cell cycle, and thus no corresponding contribution of proapoptotic activity. Interestingly, the 
B A 
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36(Z)-39(S) isomer 188, which has almost identical overall antiproliferative activity to 187, 
shows a marked apoptic effect at 100 μM. 
In order to evaluate the proapoptotic effect of the three compounds more accurately, Annexin 
V/Sytox experiments were performed. The Annexin V affinity assay can be used to determine 
the number of cells undergoing apoptosis since negatively charged Ptd-L-Ser (3), which Annexin 
V binds to, becomes available in apoptosis. 353 Similarly, the Sytox experiment uses a high 
affinity nucleic acid stain (Sytox) which does not penetrate membranes of live eukaryotic cells. 
354 The results showed a mild apoptotic effect for bistramide A (30, 77% viable cells at 100 μM), 
while little or no apoptosis was induced by the 36(Z)-39(S) isomer 188 (85% viable cells at 100 
μM).  On the other hand, a definite apoptotic effect was seen for the 36(Z)-39(R) isomer 187 
(57% viable cells at 100 μM). 
CD11b immunolabeling studies were performed to evaluate CD11b expression as a marker of 
differentiation. Bistramide A (30) showed a mild induction of CD11b expression at lower 
concentrations (36% of CD11b positive cells at 10 μM). Interestingly, the 36(Z)-39(R) isomer 
187, which showed little or no proapoptotic effect, induced a marked expression of CD11b (66% 
of cells at 100 μM).  Conversely, the 36(Z)-39(S) isomer 188, showed only a weak expression of 
CD11b (24% of cells at 100 μM). These results suggest that CD11b expression may also be an 
indirect effect of actin binding. 
In conclusion, these results confirm the existence of all three reported effects, and confirm 
that accumulation of 4n polyploid cells represents the primary mode of action of the natural 
compound. However, the results also show that the antimitotic and proapoptotic are independent 
effects of bistramide A (30), as opposed to secondary effects of actin binding. Furthermore, to 
determine whether induction of differentiation is dependent or independent of actin binding 
additional analogs have to be investigated. 
 
 
5.3 Synthesis of urea-based anaplastic lymphoma kinase inhibitors 
and SAR of the compounds (IV) 
 
At the beginning of the project, lead templates (189-194) had been discovered in a virtual 
screening of the ZINC database using a homology model of ALK (Figure 50). IV These lead 
templates were subjected to two in vitro assays; an inhibition assay using the isolated enzyme 
and a proliferation inhibition assay using NPM-ALK-transduced BaF3 cells. Non-transduced 
BaF3 cell lines were used as a control. Using the results from these initial biological studies of 
the leads 189-192 and a careful investigation of why doramapimod (78) 294 only weakly binds to 
ALK and why sorafenib (79) 295 does not, a set of novel ureas was designed. The compounds 
were designed to investigate possible gatekeeper interactions as modeling suggested that ring 2 
of the lead templates 189-194 is in close proximity to the gatekeeper residue Leu1196. In 
addition, we wanted to design compounds that would form hydrogen bonds to the hinge region 
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backbone residues Glu1197, Met1199 or Ala1200 by inserting a polar group at ring 1. As the 
initial results from the biological screening showed low cellular activity, one additional aim was 
to increase the cell penetration of the compounds while keeping the non-transduced BaF3 cells 
untouched. Furthermore, we wanted to enhance the inhibition potency by substituting rings 1-4 
with different substituents or varying the linker length of 189-194. Keeping these aims in mind, a 
set of 24 ureas was designed, synthesized and assayed for inhibition activity (Tables 2-4). IV 
 
Figure 50 Lead templates (189-194) discovered by virtual screening. IC50 values of ALK, BaF3 NPM-
ALK+ cells and BaF3 parental cells are shown. 
Figure 51 shows three methods used in the synthesis of nonsymmetric ureas (197). Method A 
was used in the cases when the isocyanate (195) and the amine (196) were commercially 
available. However, in other cases we explored various urea formation methods. Method B 
represents urea formation by the reaction of phosgene (199) with an aniline (198) and subsequent  
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Figure 51 Methods used in the synthesis of the nonsymmetric ureas presented in this investigation. 
condensation of the other aniline (196). However, this method was found to give low yields of 
the desired products and required extensive purification. IV In method C the amine (198) is 
activated as the 2,2,2-trichloroethylcarbamate (201) followed by condensation of the second 
amine (196) to yield the urea (197). This method proved to be convenient since the carbamates 
were stable, easily isolable and yielded the desired ureas after subsequent microwave irradiation 
of the second amines. IV Therefore, method C was used in the syntheses of most of the ureas 
where commercially available isocyanates were not available. The reaction conditions presented 
in original publication IV were not systematically optimized since more emphasis was put on 
producing derivatives than optimizing reaction yields. The rest of the methods used in the 
syntheses of the compounds can be found in the original publication IV. 
The IC50 values of ureas 189 and 202-204 showed that a para chlorine at ring 4 of the lead 
template 189 was the best substituent at this position of the tested ones (chlorine, methyl, 
methoxy and hydrogen, Table 2, see lead template 189 in Figure 50 for the atom numbering). 
Even though a methoxy group at the para position (compound 204) led to a slightly decreased 
binding potency, it remarkably enhanced (by > 20 times) the cellular activity. Interestingly, 
compound 205, which otherwise has the same structure as urea 204 but the methyl of the 
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pyrazole ring (ring 3) is missing, did not show any cellular activity. In compound 206 the para 
chlorine at ring 4 was kept and another chlorine was inserted at C2 of ring 2 to potentially create 
an interaction with the gatekeeper residue Leu1196 (see Figure 30). Again, good cellular activity 
could be obtained but the IC50 value of the isolated enzyme slightly increased. The slightly 
increased value may be due to the protein having to undergo a small conformational change to 
get the chlorine of 206 to fit or then ring 2 has to undergo a small tilt. By moving the C2 chlorine 
of ring 2 in 206 to the para position of ring 1 (compound 207), the inhibition activity improved, 
however, no cellular activity was obtained. In urea 208, the para chlorine of ring 4 was moved to 
the meta position. Although this small structural difference, compared to lead template 189, did 
not improve the inhibition of enzyme activity, it remarkably improved the cellular activity by 
more than 70 times. In lead compound 190, the para chlorine found in 189 is missing, however, 
the enzymatic activity of 190 is better than that of 189 (IC50 of 0.7 and 0.9 μM, respectively). 
 
Table 2. IC50 values of the pyrazolyl urea derivatives 189, 190 and 202-214 determined in cell-free 
assays using purified recombinant ALK kinase and in cell proliferation. The values are 
expressed as the mean ± sem (n = 3). 
    
Cmpd R1 R2 R3 R4 R5 R6 
ALK 
IC50 (μM) 
BaF3 
Parental 
IC50 (μM) 
BaF3 
NPM-ALK 
IC50 (μM) 
189 BnO H Me H H Cl 0.87 ± 0.11 > 100 > 100 
190 BnO H Ph H H H 0.71 ± 0.02 > 20 > 20 
202 BnO H Me H H H 2.3 ± 0.3 74 ± 4 49 ± 3 
203 BnO H Me H H Me 4.3 ± 1.9 > 100 > 100 
204 BnO H Me H H OMe 4.5 ± 1.2 4.1 ± 0.1 4.6 ± 1.1
205 BnO H H H H OMe 1.8 ± 0.5 > 100 > 100 
206 BnO Cl Me H H Cl 2.6 ± 0.2 3.1 ± 1.4 1.8 ± 1.4 
207 4-Cl-BnO H Me H H Cl 0.79 ± 0.07 > 100 > 100 
208 BnO H Me H Cl H 0.82 ± 0.03 3.0 ± 0.6 1.4 ± 0.1 
209 BnO H Ph H H Cl 1.7 ± 0.1 8.4 ± 2.2 1.4 ± 0.4 
210 BnO H Ph Cl H H 0.61 ± 0.28 5.4 ± 1.5 0.70 ± 0.22 
211 PhO H Me H H Cl 2.5 ± 0.05 16 ± 7 5 ± 2 
212 PhCO H Me H H Cl 4.1 ± 2.1 0.6 ± 0.04 2.6 ± 0.4
213 H Bn Me H H Cl 2.3 ± 0.8 25 ± 3 32 ± 2 
214 a [5-(4-Cl-Ph)-2-Me-2H-pyrazol-3-yl]2CO 0.87 ± 0.11 > 100 > 100 
a Compound 214 is a C2-symmetric urea. 
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Since compound 189 showed a better IC50 than 202 and it has a chlorine in the para position of 
ring 4, the incorporation of a para chlorine into ring 4 of the lead compound 190 was pursued. 
However, the urea 209 showed a decrease in enzymatic activity but a good cellular activity with 
an increased specificity. Interestingly, when the chlorine in ring 4 was moved from the para 
position of 209 to the ortho position of 210, the enzymatic (IC50 of 0.61 μM) and the cellular 
activity, (IC50 of 0.70 μM of BaF3 NPM-ALK-positive cells) as well as the specificity increased 
(IC50 of 5.4 μM for parental BaF3 cells). Results from proliferation and apoptosis assays further 
illustrated the anti-tumor effects of compound 210. The IC50 value for the human ALCL-derived 
cell line SU-DHL-1 (NPM-ALK-positive) was 0.8 μM and it induced apoptosis in the same cell 
line. In contrast to the NPM-ALK-positive cells, compound 210 was significantly less toxic to 
the NPM-ALK-negative human leukemic cells U937. The obtained IC50 value was only 3.2 μM. 
Compounds 211 and 212 were designed to investigate how a shorter linker of the lead 
template 189 would affect activity. Both compounds showed an increased cellular activity, 
however, the enzymatic activity decreased. Urea 213, with a benzyl substituent at C2, also 
showed a slight decrease in binding affinity, apparently for the same reason as compound 206 
(vide supra). However, 213 showed worse cellular activity than 206. 
Compounds 215-218 were designed and synthesized in an attempt to establish a hydrogen 
bond in the hinge region of ALK (Table 3). The nitrogen of the pyridine ring in 215 and 216, and 
 
Table 3. IC50 values of pyrazolyl urea derivatives 215-218 determined in cell-free assays using 
purified recombinant ALK kinase and in cell proliferation. The values are expressed as the 
mean ± sem (n = 3). 
    
Cmpd R1 R2 R3 R4 R5 R6
ALK 
IC50 (μM)
BaF3 
Parental 
IC50 (μM) 
BaF3 
NPM-ALK 
IC50 (μM) 
215 
 
H Me H H Cl 15 ± 2 0.14 ± 0.05 0.38 ± 0.04 
216 
 
H Me H H H > 100 3.5 ± 0.2 7.1 ± 1.1 
217 
 
H Me H H H > 100 22 ± 7 27 ± 7 
218 
 
H Me H H Cl 41 ± 2 5.0 ± 1.0 3.2 ± 1.3 
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the oxygen in the morpholino group of 217 and 218 were suggested by modeling to form the 
same kind of hydrogen bond with Met1199 of the backbone as can be obtained for PHA-E429 
(72) in the crystal structure of ALK, for example (Figure 52). However, compounds 215-218 
showed weak binding to ALK but may target some other kinases in the cells, particularly 215, 
which showed high cellular activity (IC50 of 0.14 μM for parental BaF3 cells). Interestingly, the 
cellular activity of urea 215, with a para chlorine in ring 4, was 25 times higher than for urea 
216, which has an unsubstituted ring 4. 
 
Figure 52 An enlargement of compound 210 docked into the kinase domain of the homology model of 
ALK superimposed on the crystal structure of ALK in complex with PHA-E429 (72) (PDB 
ID: 2XBA). 281 The compounds are presented in ball and stick representations and colored 
by atom type; carbons (210: beige and PHA-E429 (72): turquoise), nitrogens (blue), 
oxygens (red) and chlorines (light green). The Glu1197, Met1199 and Ala1200 residues of 
the hinge region are shown in ball and sticks and are colored by atom type. Hydrogen bonds 
between the hinge region residues and PHA-E429 (72) are denoted with green spheres. The 
figure was created using ICM Molsoft software 3.7. 
The lead templates 191-192 were also modified in an attempt to increase their enzymatic and 
cellular activities. Noticeably, from the initial screening results of these candidates, the amide 
groups of 192 were not involved in hydrogen bonding to the protein as the IC50 values of 191 and 
192 were similar (0.4 and 0.3 μM, respectively). Therefore, in a similar way as the modifications 
done for lead templates 189-190, the possibility of forming hydrogen bonds to the hinge region 
by adding a hydrogen acceptor group to the ring 1 of 191 and 192 was investigated. However, 
compounds 219-221 showed a slightly decreased binding affinity for ALK compared to lead 
templates 191 and 192 (Table 4). Compounds 223-225 were synthesized and tested for binding 
affinity in an attempt to find additional interactions with the gatekeeper Leu1196 or to 
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investigate the required linker length of the compounds. Again, the enzymatic activities could 
not be improved but the cellular activities increased for compounds 224 and 225. It is hard to 
speculate on the binding modes of these compounds since the structures and the relative 
symmetry of the compounds allows them to bind in several ways. In conclusion, the enzymatic 
activity could not be improved; however, the cellular activity was increased significantly. 
 
Table 4. IC50 values of phenyl urea derivatives 191-194 and 219-225 determined using purified ALK 
kinase domain and the effects of these compounds on cell proliferation. The values are 
expressed as the mean ± sem (n = 3). 
 
 
   
Cmpd R1 R2 R3 R4 
ALK 
IC50 (μM)
BaF3 
Parental 
IC50 (μM) 
BaF3 
NPM-ALK 
IC50 (μM) 
191 BnO H H OBn 0.44 ± 0.08 > 100 > 100 
192 
 
H H 0.3 ± 0.03 > 100 > 100 
193 
 
H H OBn 0.26 ± 0.09 > 20 > 20 
194 a 
 
- H OBn 0.38 ± 0.08 > 20 > 20 
219 
 
H H OBn 0.80 ± 0.12 61 ± 13 42 ± 5 
220 
 
H OBn 3.6 ± 0.7 > 100 86 ± 1 
221 
 
H H OBn 8.9 ± 3.2 > 100 > 100 
222 
 
H H OBn 0.39 ± 0.1 > 100 > 100 
223 BnO Cl Cl OBn 1.7 ± 0.2 44 ± 6 50 ± 8 
224 PhO H H OBn 5.0 ± 0.2 10 ± 5 1.5 ± 0.9 
225 H Bn H OBn-4-Cl 2.0 ± 0.4 7.1 ± 0.2 11 ± 1 
a Compound 194 has a 6-[(7-chloroquinazolin-4-yl)oxy]pyridin-3-yl ring as ring 2, see Figure 50. 
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 6 Summary and conclusions 
A totally new class of compounds binding the regulatory domain of PKC was identified in this 
study. The set of 31 dialkyl 5-(hydroxymethyl)isophthalates presented here were conveniently 
synthesized in only four steps and with overall yields of 8-78%. The compounds were shown to 
displace radioactively labeled [3H]PDBu from PKC and PKC in a concentration-dependent 
manner, thus providing evidence that they target the C1 domain. The best compounds (114, 128, 
and 129, with 3-(trifluoromethyl)benzyl,  3-hexyl  and 3-heptyl ester groups, respectively) 
showed Ki values in the 200-900 nM range. Comparing the Ki values obtained between PKC 
and PKC there was a modest selectivity in the binding affinities for PKC. However, compound 
114 was able to displace a substantially smaller proportion of [3H]PDBu from PKC than from 
PKC. SAR studies of the synthesized compounds demonstrated not only the important 
functional groups for binding to the C1 domain, but also that modifications of these groups 
diminished binding activity. Interestingly, while derivatives 114 and 128 induced PKC-
dependent ERK phosphorylation in HeLa cells, compound 129, structurally different from 128 
only by one carbon in the side chains, was unable to induce ERK phosphorylation. Instead, 
derivative 129 inhibited phorbol-induced ERK phosphorylation. The reason why the 
isophthalates 114 and 128 functioned as PKC agonists but the very similar analog 129 as an 
antagonist remained unclear. 
Derivatives 114 and 119 (with 3-(trifluoromethyl)benzyl and 1-hexyl ester groups, 
respectively) were shown to induce apoptosis already during the first two hours in HL-60 
leukemia cells while they were not cytotoxic or mutagenic in Swiss 3T3 fibroblasts. Future work 
should focus on the pharmacology of these ligands, making them more drug-like. Emphasis 
should be put on improving the binding affinity and the specificity among C1 domain containing 
proteins. 
 
In this study the total syntheses of the natural compound bistramide A (30) and the new 
36(Z)-39(R) (187) and 36(Z)-39(S) (188) isomers of bistramide A were finished in co-operation 
between three laboratories. The central fragment (173) of bistramide A (30) prepared in this 
investigation was successfully performed in seven steps with an overall yield of 21%. The 
synthesis route of the central fragment (173) relied on an asymmetric crotyltitanation, allowing 
us to avoid the use of highly volatile trans-2-butene used in the Kozmin route. The highly face-
selective crotyltitanium complex (181) used in the introduction of the right stereochemistry of 
the central fragment (173) was found to work well in this reaction. 
The overall antiproliferative activities of the isomers were shown to be similar, however, 
each compound showed a distinct distribution of antimitotic effect, proapoptotic effect, and pro-
differentiation effect. Accumulation of 4n polyploid cells was confirmed to represent the primary 
mode of action for the antiproliferative effect of bistramide A (30). In addition, it was shown that 
the antimitotic and proapoptotic effects of bistramide A (30) were independent effects and not 
secondary to actin binding. However, whether the induction of differentiation is dependent or 
independent of actin binding remains to be seen. 
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A third aim in this study was to design and synthesize a new class of type II inhibitors 
targeted at the kinase domain of ALK. Most of the compounds were conveniently prepared in 
only one reaction step using commercially available isocyanates and amines. In addition, urea 
formation was performed by activating one of the amines and subsequent condensation of the 
other. Of the activation methods investigated, activating the amines as 2,2,2-
trichloroethylcarbamates was found to be the superior method, since the carbamates were 
isolable and cleanly yielded the desired ureas with the second amines after subsequent 
microwave irradiation. 
The set of twenty-five 1,3-disubstituted ureas presented here showed IC50 values as low as 
390 nM and, more importantly, selective antiproliferative activity on ALK-positive cells was 
achieved. The best inhibitor (210) inhibited the cell growth of ALK-positive cell lines BaF3 
(NPM-ALK-positive) and SU-DHL-1 with IC50 values of 0.6 and 0.8 μM, respectively. The 
compound 210 was less toxic to the NPM-ALK-negative human leukemic cells U937 (IC50 = 3.2 
μM) and BaF3 parental cells (IC50 = 5.4 μM). SAR studies of the synthesized compounds 
revealed functional groups and positions of the scaffold, which enhanced the enzymatic and 
cellular activities. Even though these inhibitors were modeled to mainly bind outside the ATP-
binding pocket, attempts to create interactions with the hinge region of these type II inhibitors 
did not succeed. Indeed, future inhibitors should be designed to explore possible interactions 
with the hinge region and also to improve the drug-like properties. 
 
Unfortunately, the results of this study do not resolve the cancer problem. However, the more 
realistic aims were to contribute new knowledge into the field. Even though the achieved binding 
affinities of the PKC regulatory domain-targeted compounds presented in this study were not in 
the low nanomolar range, which some natural compounds display, the compounds are widely 
sought new chemical entities of the C1 domain. As there are no clinically available C1 domain-
targeted drugs on the market and natural compounds are generally laborious to prepare, the 
newly synthesized compounds as well as the SAR information provided by this investigation 
may be useful in the future for researchers developing potential cancer drugs. Analogues of 
prostratin, bryostatins, aplysiatoxin, indo- and benzolactams and DAG-lactones may be among 
these. 
The results from the other kinase studied, ALK, are very promising since we were able to 
develop an inhibitor with submicromolar in vitro activity, growth inhibitory activity on cancer 
cell lines as well as selectivity of 10-fold in favor of BaF3 NPM-ALK-positive cells compared to 
BaF3 parental cells. In addition, since the inhibitors were designed to target the inactive 
conformation of the catalytic domain of ALK, they may prove to show selectivity among other 
enzymes. However, this remains to be seen. 
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